The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
Tumors or cancer of the LUNG.
Tumors or cancer of the LIVER.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Tumors or cancer of the SKIN.
Tumors or cancer of the human BREAST.
A cell line derived from cultured tumor cells.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
A malignant epithelial tumor with a glandular organization.
Tumors or cancers of the KIDNEY.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Tumors or cancer of the THYROID GLAND.
Neoplasms containing cyst-like formations or producing mucin or serum.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Tumors or cancer of the STOMACH.
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
Tumors or cancer of the COLON.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
Tumors or cancer of the PROSTATE.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Tumors or cancer of the SPLEEN.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
DNA present in neoplastic tissue.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA.
A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.
Tumors or cancer of the EYE.
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS.
Tumors or cancer of the PAROTID GLAND.
Tumors or cancer located in muscle tissue or specific muscles. They are differentiated from NEOPLASMS, MUSCLE TISSUE which are neoplasms composed of skeletal, cardiac, or smooth muscle tissue, such as MYOSARCOMA or LEIOMYOMA.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Tumors or cancer of the PERITONEUM.
Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.
Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.
Transplantation between animals of different species.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
Tumors or cancer of the APPENDIX.
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966)
Tumors or cancer of the ENDOCRINE GLANDS.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
The local implantation of tumor cells by contamination of instruments and surgical equipment during and after surgical resection, resulting in local growth of the cells and tumor formation.
Excision of all or part of the liver. (Dorland, 28th ed)
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Tumors or cancer of the INTESTINES.
Neoplasms of the bony part of the skull.
Tumors or cancer of the MOUTH.
Experimentally induced tumors of the LIVER.
Tumors or cancer of the BILE DUCTS.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
Tumors or cancer of the SALIVARY GLANDS.
Tumors or cancer of the MAMMARY GLAND in animals (MAMMARY GLANDS, ANIMAL).
Tumors or cancer of the UTERUS.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
Tumors or cancer of the TONGUE.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
A benign epithelial tumor with a glandular organization.
Tumors or cancer of the RECTUM.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
Tumors or cancer of the MANDIBLE.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
Phenotypic changes of EPITHELIAL CELLS to MESENCHYME type, which increase cell mobility critical in many developmental processes such as NEURAL TUBE development. NEOPLASM METASTASIS and DISEASE PROGRESSION may also induce this transition.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)
Tumors or cancer of the NOSE.
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
Elements of limited time intervals, contributing to particular results or situations.
Exfoliate neoplastic cells circulating in the blood and associated with metastasizing tumors.
Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.
A family of nucleotide diphosphate kinases that play a role in a variety of cellular signaling pathways that effect CELL DIFFERENTIATION; CELL PROLIFERATION; and APOPTOSIS. They are considered multifunctional proteins that interact with a variety of cellular proteins and have functions that are unrelated to their enzyme activity.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Tumors or cancer of the ESOPHAGUS.
Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.
Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.
Surgery to remove one or more NEOPLASM METASTASES.
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Tumors or cancer of the BRONCHI.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Tumors or cancer of the URINARY BLADDER.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.
A general term for various neoplastic diseases of the lymphoid tissue.
Tumors or cancer of the DUODENUM.
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.
Cancer or tumors of the MAXILLA or upper jaw.
Tumors or cancer of the THYMUS GLAND.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
Tumors or cancer of the ADRENAL GLANDS.
Neoplasms composed of more than one type of neoplastic tissue.
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
Adherence of cells to surfaces or to other cells.
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Tumors or cancer of the gallbladder.
Tumors or cancer in the ILEUM region of the small intestine (INTESTINE, SMALL).
A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)
Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Tumors or cancer of the MEDIASTINUM.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
An imaging technique using compounds labelled with short-lived positron-emitting radionuclides (such as carbon-11, nitrogen-13, oxygen-15 and fluorine-18) to measure cell metabolism. It has been useful in study of soft tissues such as CANCER; CARDIOVASCULAR SYSTEM; and brain. SINGLE-PHOTON EMISSION-COMPUTED TOMOGRAPHY is closely related to positron emission tomography, but uses isotopes with longer half-lives and resolution is lower.
Tumors or cancer of the UVEA.
RNA present in neoplastic tissue.
A radiological stereotactic technique developed for cutting or destroying tissue by high doses of radiation in place of surgical incisions. It was originally developed for neurosurgery on structures in the brain and its use gradually spread to radiation surgery on extracranial structures as well. The usual rigid needles or probes of stereotactic surgery are replaced with beams of ionizing radiation directed toward a target so as to achieve local tissue destruction.
A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)
Neoplasms of the thin serous membrane that envelopes the lungs and lines the thoracic cavity. Pleural neoplasms are exceedingly rare and are usually not diagnosed until they are advanced because in the early stages they produce no symptoms.
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
Calcium-dependent cell adhesion proteins. They are important in the formation of ADHERENS JUNCTIONS between cells. Cadherins are classified by their distinct immunological and tissue specificities, either by letters (E- for epithelial, N- for neural, and P- for placental cadherins) or by numbers (cadherin-12 or N-cadherin 2 for brain-cadherin). Cadherins promote cell adhesion via a homophilic mechanism as in the construction of tissues and of the whole animal body.
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Area of the human body underneath the SHOULDER JOINT, also known as the armpit or underarm.
Neoplasms of the bony orbit and contents except the eyeball.
The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
A diagnostic procedure used to determine whether LYMPHATIC METASTASIS has occurred. The sentinel lymph node is the first lymph node to receive drainage from a neoplasm.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
An endopeptidase that is structurally similar to MATRIX METALLOPROTEINASE 2. It degrades GELATIN types I and V; COLLAGEN TYPE IV; and COLLAGEN TYPE V.
The formation of LYMPHATIC VESSELS.
Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents.
A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
Tumors or cancer of the pelvic region.
An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.
Surgical removal of the pancreas. (Dorland, 28th ed)
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
The exposure of the head to roentgen rays or other forms of radioactivity for therapeutic or preventive purposes.
Tumors or cancer located in bone tissue or specific BONES.
Tumors or cancer of the NASOPHARYNX.
A sarcoma containing large spindle cells of smooth muscle. Although it rarely occurs in soft tissue, it is common in the viscera. It is the most common soft tissue sarcoma of the gastrointestinal tract and uterus. The median age of patients is 60 years. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1865)
Primary or metastatic neoplasms of the CEREBELLUM. Tumors in this location frequently present with ATAXIA or signs of INTRACRANIAL HYPERTENSION due to obstruction of the fourth ventricle. Common primary cerebellar tumors include fibrillary ASTROCYTOMA and cerebellar HEMANGIOBLASTOMA. The cerebellum is a relatively common site for tumor metastases from the lung, breast, and other distant organs. (From Okazaki & Scheithauer, Atlas of Neuropathology, 1988, p86 and p141)
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
Tumors or cancers of the ADRENAL CORTEX.
Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female.
Tumors or cancer of the VAGINA.
A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)
Using fine needles (finer than 22-gauge) to remove tissue or fluid specimens from the living body for examination in the pathology laboratory and for disease diagnosis.
Tumors of the choroid; most common intraocular tumors are malignant melanomas of the choroid. These usually occur after puberty and increase in incidence with advancing age. Most malignant melanomas of the uveal tract develop from benign melanomas (nevi).
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.
The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)
Surgical removal of the thyroid gland. (Dorland, 28th ed)
Dissection in the neck to remove all disease tissues including cervical LYMPH NODES and to leave an adequate margin of normal tissue. This type of surgery is usually used in tumors or cervical metastases in the head and neck. The prototype of neck dissection is the radical neck dissection described by Crile in 1906.
Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)
Tumors or cancer of the anal gland.
A widely expressed transmembrane glycoprotein that functions as a METASTASIS suppressor protein. It is underexpressed in a variety of human NEOPLASMS.
Benign and malignant neoplastic processes arising from or involving components of the central, peripheral, and autonomic nervous systems, cranial nerves, and meninges. Included in this category are primary and metastatic nervous system neoplasms.
Tumor or cancer of the COMMON BILE DUCT including the AMPULLA OF VATER and the SPHINCTER OF ODDI.
The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth.
Neoplasms which arise from peripheral nerve tissue. This includes NEUROFIBROMAS; SCHWANNOMAS; GRANULAR CELL TUMORS; and malignant peripheral NERVE SHEATH NEOPLASMS. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp1750-1)
A secreted endopeptidase homologous with INTERSTITIAL COLLAGENASE, but which possesses an additional fibronectin-like domain.
Tumors or cancer of any part of the hearing and equilibrium system of the body (the EXTERNAL EAR, the MIDDLE EAR, and the INNER EAR).

Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis. (1/13013)

The Met tyrosine kinase - the HGF receptor - induces cell transformation and metastasis when constitutively activated. Met signaling is mediated by phosphorylation of two carboxy-terminal tyrosines which act as docking sites for a number of SH2-containing molecules. These include Grb2 and p85 which couple the receptor, respectively, with Ras and PI 3-kinase. We previously showed that a Met mutant designed to obtain preferential coupling with Grb2 (Met2xGrb2) is permissive for motility, increases transformation, but - surprisingly - is impaired in causing invasion and metastasis. In this work we used Met mutants optimized for binding either p85 alone (Met2xPI3K) or p85 and Grb2 (MetPI3K/Grb2) to evaluate the relative importance of Ras and PI 3-kinase as downstream effectors of Met. Met2xPI3K was competent in eliciting motility, but not transformation, invasion, or metastasis. Conversely, MetP13K/Grb2 induced motility, transformation, invasion and metastasis as efficiently as wild type Met. Furthermore, the expression of constitutively active PI 3-kinase in cells transformed by the Met2xGrb2 mutant, fully rescued their ability to invade and metastasize. These data point to a central role for PI 3-kinase in Met-mediated invasiveness, and indicate that simultaneous activation of Ras and PI 3-kinase is required to unleash the Met metastatic potential.  (+info)

Control of metastasis by Asn-linked, beta1-6 branched oligosaccharides in mouse mammary cancer cells. (2/13013)

Studies in cell lines and malignant human tissues have shown that increased cell-surface Asn-linked beta1-6(GlcNAcbeta1-6Man) branching is associated with increased tumorigenic and metastatic properties. In this study, three mouse mammary cancer cell lines were transfected with an expression vector containing the mouse cDNA for N-acetylglucosaminyltransferase V (GlcNAcT-V EC, the glycosyltransferase responsible for initiating beta1-6 branching on Asn-linked carbohydrates. The cell lines were screened for increased cytotoxicity to L-PHA, a lectin specific for beta1-6 branching structures. Cell lines exhibiting increased L-PHA cytotoxicity expressed increased levels of beta1-6 branching structures. Northern blots detected the presence of GlcNAcT-V transcribed from the expression vector in the L-PHA sensitive cell lines. After injection into the tail veins of mice, transfected cell lines with increased beta1-6 branching on the cell surface formed elevated levels of lung tumors relative to control transfected cell lines (P < 0.002). Western blots of membrane proteins from GlcNAcT-V transfected and control cells probed with the lectins DSA and WGA did not show an increase in polyN-acetyllactosamine and sialic acid content in the transfected cell lines. These results demonstrate that a specific increase in beta1-6 branching due to an elevation in GlcNAcT-V expression increases metastatic potential.  (+info)

Role of thrombin receptor in breast cancer invasiveness. (3/13013)

Invasion, the ability of an epithelial cancer cell to detach from and move through a basement membrane, is a central process in tumour metastasis. Two components of invasion are proteolysis of extracellular matrix and cellular movement through it. A potential promoter of these two processes is thrombin, the serine proteinase derived from the ubiquitous plasma protein prothrombin. Thrombin promotes the invasion of MDA-MB231 breast tumour cells (a highly aggressive cell line) in an in vitro assay. Invasion by MDA-MB436 and MCF-7 cells, less aggressive cell lines, is not promoted by thrombin. Thrombin, added to the cells, is a stimulator of cellular movement; fibroblast-conditioned medium is the chemotaxin. Thrombin-promoted invasion is inhibited by hirudin. Stimulation of invasion is a receptor-mediated process that is mimicked by a thrombin receptor-activating peptide. Thrombin has no effect on chemotaxis in vitro. Thrombin receptor is detectable on the surface of MDA-MB231 cells, but not on the other two cell lines. Introduction of oestrogen receptors into MDA-MB231 cells by transfection with pHEO had no effect on thrombin receptor expression, in the presence or absence of oestradiol. This paper demonstrates that thrombin increases invasion by the aggressive breast cancer cell line MDA-MB231 by a thrombin receptor-dependent mechanism.  (+info)

Development of a sensitive, specific reverse transcriptase polymerase chain reaction-based assay for epithelial tumour cells in effusions. (4/13013)

We developed a sensitive and specific method for the detection of epithelial cancer cells in effusions with a two-stage molecular-based assay which combined enrichment for cancer cells by immunomagnetic bead selection and reverse transcriptase polymerase chain reaction (RT-PCR) detection of epithelial glycoprotein 2 (EGP-2) RNA. Preliminary experiments indicated that immunobead selection was essential to avoid occasional false-positive RT-PCR results, and this method detected ten breast cancer cells electively added to 10(7) cytologically negative effusion cells. We studied 110 cases of pleural (n = 68) and peritoneal (n = 42) effusions (30 from patients with known carcinoma and 80 from those without known carcinoma), and the results were compared with cytological findings. Of 18 effusions that were cytologically positive or suspicious for malignant cells, 17 (94%) were positive for EGP-2 RNA (the one negative sample was from a patient who recently received combination chemotherapy). Of 92 cytologically negative samples, 11 (12%) were positive for EGP-2, including six patients with a history of previous or current carcinoma. Our method appears to be highly specific and increases the sensitivity of detection of malignant cells; it may be a useful adjunct to routine cytopathological examination.  (+info)

Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. (5/13013)

Tissue factor (TF) is an initiator of the extrinsic cascade of blood coagulation. Although recent studies have revealed a relationship between metastatic properties and TF expression in some neoplastic cells, the significance of TF in lung cancer, especially in non-small-cell lung cancer (NSCLC), is still unclear. In this study, TF was detected in NSCLC cell lines by functional study, Western blot analysis and immunocytochemical staining. TF levels in eight NSCLC cell lines were also quantitated by enzyme-linked immunosorbent assay (ELISA), and TF expression was evaluated in 55 specimens of surgically resected NSCLCs. NSCLC cell lines derived from metastatic lesions produced high levels of TF (48.3+/-23.5 ng 10(-6) cells, mean +/- s.e.m.), whereas those derived from primary lesions produced low levels of TF (0.2+/-0.1 ng 10(-6) cells). Immunohistochemical studies disclosed significantly stronger staining for TF in cells from NSCLC patients with metastasis than in those without metastasis. Among the 28 patients with metastasis, ten were strongly positive, 16 were moderately positive and two were negative for TF. In contrast, among the 27 patients without metastasis, only two were strongly positive, 18 were moderately positive and seven were negative for TF. Therefore, malignant cells from patients with lung cancer produce various levels of TF, and TF may play an important role in the metastatic process.  (+info)

Peritoneal cytology in the surgical evaluation of gastric carcinoma. (6/13013)

Many patients undergoing surgery for gastric carcinoma will develop peritoneal metastases. A method to identify those patients at risk of peritoneal recurrence would help in the selection of patients for adjuvant therapy. Peritoneal cytology has received little attention in the West, but may prove a useful additional means of evaluating patients with gastric cancer. The aims of this study were to evaluate sampling techniques for peritoneal cytology in patients with gastric cancer, to assess the prognostic significance of free peritoneal malignant cells and to discover the effect of the operative procedure on dissemination of malignant cells. The study is based on 85 consecutive patients undergoing surgical treatment of gastric cancer and followed up for 2 years or until death. Peritoneal cytology samples were collected at laparoscopy, and at operation prior to resection by intraperitoneal lavage and serosal brushings. After resection, samples were taken by peritoneal lavage, imprint cytology of the resected specimen and post-operatively by peritoneal irrigation via a percutaneous catheter. Malignant cells were diagnosed by two independent microscopists. Preoperative peritoneal lavage yielded malignant cells in 16 out of 85 cases (19%). The yield of free malignant cells was increased by using serosal brushings (by four cases) and imprint cytology (by two cases); all of the cases had evidence of serosal penetration. One serosa-negative case exhibited positive cytology in the post-resection peritoneal specimen in which the preresection cytology specimen was negative. Survival was worse in the cytology-positive group (chi2 = 25.1; P< 0.0001). Among serosa-positive patients, survival was significantly reduced if cytology was positive, if cases yielded by brushings and imprint cytology were included (log-rank test = 8.44; 1 df, P = 0.004). In conclusion, free peritoneal malignant cells can be identified in patients with gastric cancer who have a poor prognosis; the yield can be increased with brushings and imprint cytology in addition to conventional peritoneal lavage. Evaluation of peritoneal cytology by these methods may have a role in the selection of patients with the poorest prognosis who may benefit most from adjuvant therapy.  (+info)

Expression of pyrimidine nucleoside phosphorylase mRNA plays an important role in the prognosis of patients with oesophageal cancer. (7/13013)

To clarify the significance of the expression of pyrimidine nucleoside phosphorylase (PyNPase) mRNA as a predictive factor for the prognosis of patients with oesophageal carcinoma, the PyNPase mRNA in the tumours and normal tissues from 55 resected cases of oesophageal carcinoma was examined by a reverse transcription polymerase chain reaction (RT-PCR). As a result, a positive correlation was observed between the tumour/normal (T/N) ratio of the expression of PyNPase mRNA by RT-PCR and that of the enzyme activity of PyNPase based on the findings of an enzyme linked immunosolvent assay (r = 0.594, P = 0.009). The T/N ratio of the expression of PyNPase mRNA was significantly higher in the cases with lymph vessel invasion (P = 0.013), lymph node metastasis (P = 0.0016), and an advanced stage of the disease (P = 0.021) than those without these factors. The patients with a higher T/N ratio of PyNPase mRNA showed significantly worse prognosis than those with a lower T/N ratio (P = 0.023 with log-rank tests). A multivariate analysis for the cumulative survival rates revealed that a high T/N ratio of the expression of PyNPase mRNA was independently related to a poor prognosis. These findings suggested that the determination of PyNPase mRNA by RT-PCR thus appears to be a new useful parameter for identifying both a poor prognosis and a highly malignant potential of oesophageal carcinoma.  (+info)

Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer. (8/13013)

Motivated by the observation of preclinical synergy, a Phase I dose escalation study of edatrexate in combination with a 3-h paclitaxel infusion was performed in patients with advanced breast cancer to determine the maximum tolerated dose (MTD) of edatrexate and the toxicities associated with this combination and to report preliminary observations of efficacy with this novel combination. Thirty-six patients were enrolled in this Phase I trial. Thirty-five eligible patients were treated every 21 days in cohorts of at least three patients and were assessable for toxicity. One patient was ineligible due to hyperbilirubinemia. Stepwise dose escalations of edatrexate were administered until grade >3 nonhematological dose-limiting toxicities were reported. The initial dose level of edatrexate was 180 mg/m2; subsequent cohorts were treated with escalating doses of edatrexate (210, 240, 270, 300, 350, and 400 mg/m2). Edatrexate was administered by i.v. infusion over 1 h. Paclitaxel was administered 24 h later at a fixed dose of 175 mg/m2 as a 3-h infusion with standard dexamethasone, diphenhydramine, and cimetidine premedication. The MTD of edatrexate was reached at the 350 mg/m2 level in this study. Grade 3 diarrhea was seen in one patient at the 300 and 400 mg/m2 dose levels, requiring dose reductions. Two patients experienced grade 4 stomatitis at the 400 mg/m2 dose level and also required dose reduction, establishing the MTD as 350 mg/m2. Grade 3 nausea and vomiting were noted in two of three patients at the highest dose level. Of 35 patients, 4 patients reported grade 3 myalgias and 1 patient reported grade 3 neurosensory complaints, which were seen mostly at the 350 and 400 mg/m2 dose levels; however, 1 patient reported grade 3 myalgias at 180 mg/m2. No cumulative neurotoxicity was observed, and no patient experienced an allergic reaction to paclitaxel. In 23 patients with bidimensionally measurable disease, there were four complete (17%) and seven partial responses, with an overall response rate of 48% (95% confidence interval, 27-69%). All of the responses were seen in patients who had not received prior chemotherapy for stage IV disease. The median duration of response was not assessable because many responding patients went on to receive high-dose chemotherapy treatment with stem cell support. The combination of edatrexate and paclitaxel for treatment of metastatic breast cancer is a feasible and safe regimen. The MTD of edatrexate was 350 mg/m2 when combined with a 3-h infusion of paclitaxel (175 mg/m2) given 24 h later. Activity was noted even among patients who had relapsed shortly after receiving methotrexate- and/or doxorubicin-containing adjuvant regimens. Additional studies evaluating the sequences and dosing schema for this combination are warranted to improve the response proportion and define the duration of the response.  (+info)

Metastasis is a complicated multistage process that requires the coordination of multiple genes, including both metastasis stimulating genes and metastasis suppressor genes (22) . Genomic instability is one of the driving forces for tumor progression and metastasis development. Among all genetic alterations, inactivation of metastasis suppressor genes is one important factor contributing to the formation of tumor metastasis. Chromosome 11, in particular 11p, is one of the most common regions undergoing genetic alterations in human breast cancer (3, 4, 5) . A previous study demonstrated that a breast cancer metastasis gene or genes exists on chromosome 11 by the fact that the introduction of a normal copy of chromosome 11 into malignant breast cancer cells significantly suppressed their metastatic ability (6) .. The KAI1 gene, located on human chromosome 11p11.2, was initially identified as a metastasis suppressor gene for human prostate cancer (7) . Down-regulation of the KAI1 protein was ...
TY - JOUR. T1 - Adhesion Characteristics of Murine Metastatic and Nonmetastatic Tumor Cells in Vitro. AU - Murray, J. Clifford. AU - Liotta, Lance. AU - Rennard, Stephen I.. AU - Martin, George R.. PY - 1980/2/1. Y1 - 1980/2/1. N2 - We have studied the attachment of mouse fibroblasts, transformed nonmetastatic fibroblasts, and metastatic fibrosarcoma cells to various substrates. The metastatic cells attach preferentially to type IV (basement membrane) collagen in the absence of serum, compared to type I collagen and plastic. In the presence of fibronectin, these cells attach well to both type I and type IV collagens. The normal and transformed fibroblasts attach to all these substrates, although the transformed fibroblasts attach more slowly. The ability to attach to type I collagen and plastic is correlated with the levels of fibronectin and collagen produced by these cells. The data indicate that the transformed and metastatic cells differ from normal cells in their attachment properties and ...
The purpose of these studies was to determine whether hematogenous clonal pulmonary melanoma metastases originate from the expansion of a single cell and if so, by extrapolation, metastasis can be considered a cloning process. Three different cell lines of murine K-1735 melanoma with different metastatic properties and unique karyotypes were injected i.v. into syngeneic C3H/HeN mice as multicell aggregates of individual cell lines or combinations of cell lines. Resultant solitary lung metastases were isolated in culture as individual lines and then karyotyped. Even when heterogeneous clumps of tumor cells were injected, the individual metastases exhibited a karyotype unique to one metastatic cell type. Furthermore, when cellular aggregates were composed of metastatic cells admixed with cells that were tumorigenic but nonmetastatic, the resultant metastases exhibited only the karyotype of the metastatic cells. This finding suggests that the presence of metastatic cells did not change the ...
A new study with mice shows that the fight or flight response to stress can promote breast cancer metastasis to the bone.. Researchers at the Vanderbilt University Center for Bone Biology demonstrated in mice that activation of the sympathetic nervous system - the fight-or-flight response to stress - primes the bone environment for breast cancer cell metastasis. The researchers were able to prevent breast cancer cell lesions in bone using propranolol, a cardiovascular medicine that inhibits sympathetic nervous system signals.. Metastasis - the spread of cancer cells to organs and bone - is more likely to kill patients than a primary breast tumor, said Florent Elefteriou, Ph.D., director of the Vanderbilt Center for Bone Biology.. Preventing metastasis is really the goal we want to achieve, he said.. Elefteriou and his colleagues learned in previous studies that the sympathetic nervous system stimulated bone remodeling, and that it used some of the same signaling molecules that have been ...
We have developed a robust approach for imaging of BCSC growth and dissemination, which permits both macroscopic and microscopic analysis of cancer progression. In our studies, the imaging assays facilitated development of visible human-in-mouse xenograft tumor models with spontaneous metastases to lungs or local/distant lymph nodes. Our patient-tumor derived xenograft models will be able to overcome some limitations of previous metastatic models with human cancer cell lines or mouse tumor models. Spontaneous metastases present representative features of patient tumors that can be used in predictive models of metastasis and therapeutic response, but cannot be recapitulated by lung/bone colonization models via tail-vein or intracardiac injections. This point is driven home by the observation that these xenografts metastasize to the lungs but not the bones when grown in the mammary fat pads. This likely reflects that triple-negative ER− breast cancers tend to metastasize to the lungs rather ...
Cancer cell metastasis is one of the most critical steps in tumor development and is responsible for more than 80 of cancer related deaths. Among the molecules involved in promoting cancer metastasis, the role of the cell adhesion molecules, CD44 and CD146 are well known in promoting cancer cell motility and metastasis. Despite this knowledge, the molecular mechanism through which CD44 promotes tumor development and cell metastasis is still nascent. CD146 (MUC 18) was, first identified in highly metastatic melanomas. The absence of CD146 in normal melanocytes and its high expression in melanomas suggests its tumor promoting actions. Despite the association between CD146 expression and development of melanoma, its expression patterns and role in normal and metastatic breast tissues still remains controversial. This study aims to elucidate some of these discrepancies by presenting CD146 as a downstream target for CD44, in a way such that CD146 expression is related to CD44 and regulates the tumor ...
Tumor cell metastasis and proliferation are crucial for tumor development and result in loss of life of tumor individuals. TLR4 signaling pathway. It offers fresh insights for the systems of tumor advancement and metastasis, and suggests targeting TLR4 and OPN as an intervention in the ovarian cancer treatment. proliferation activity of tumor cells. Without LPS stimulation, the proliferation activity of tumor cells increased during 12 h. The cell proliferation significantly changed by LPS stimulation, and the maximum absorbance value at 429 nm was present after 6 h, with a proliferation rate of approximately 137.1% compared to cells without stimulation (Figure 2AC2B). To investigate the effect of TLR4 signal block on cell proliferation, the TLR4 inhibitor TAK-242 was used. The LPS-stimulated increase in the proliferation of tumor cells was significantly reduced with TAK-242 pretreatment, whereas no significant change was observed in cells treated with TAK-242 alone (Figure ?(Figure2C).2C). These ...
TY - JOUR. T1 - Homeoprotein Six2 promotes breast cancer metastasis via transcriptional and epigenetic control of E-cadherin expression. AU - Wang, Chu An. AU - Drasin, David. AU - Pham, Catherine. AU - Jedlicka, Paul. AU - Zaberezhnyy, Vadym. AU - Guney, Michelle. AU - Li, Howard. AU - Nemenoff, Raphael. AU - Costello, James C.. AU - Tan, Aik Choon. AU - Ford, Heide L.. PY - 2014/12/15. Y1 - 2014/12/15. N2 - Misexpression of developmental transcription factors occurs often in human cancers, where embryonic programs may be reinstated in a context that promotes or sustains malignant development. In this study, we report the involvement of the kidney development transcription factor Six2 in the metastatic progression of human breast cancer. We found that Six2 promoted breast cancer metastasis by a novel mechanism involving both transcriptional and epigenetic regulation of E-cadherin. Downregulation of E-cadherin by Six2 was necessary for its ability to increase soft agar growth and in vivo ...
Most cancer deaths are due to spreading of the primary tumor to one or several secondary sites, in a process called metastasis. These metastases are often more difficult to treat than the primary tumor and their presence marks severe progression of the disease. Tumor cell metastasis involves cell migration through heterogenous microenvironments in tissues, along anatomical features such as blood vessels and nerves, and into and out of vasculature. Mounting evidence has accumulated, demonstrating that metastatic tumor cells can migrate via several modes or mechanisms of migration, and can switch between these modes depending on the specific features of the microenvironment. Our research in this area is focused on understanding how distinct physical and biochemical cues from the tumor cells microenvironment affect the phenotype, biological signaling, mechanical properties, and interactions with other cells during metastasis. We are interested in metastasis to the brain, which is especially ...
TY - JOUR. T1 - Biopsy of breast cancer metastases. T2 - BMC Cancer. AU - Shachar,Shlomit Strulov. AU - Mashiach,Tanya. AU - Fried,Georgeta. AU - Drumea,Karen. AU - Shafran,Noa. AU - Muss,Hyman B.. AU - Bar-Sela,Gil. PY - 2017/1/4. Y1 - 2017/1/4. N2 - Background: Discordance in hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) status between primary tumors and metastatic sites for breast cancer is well established. However, it is uncertain which patient-related factors lead to biopsy when metastases are suspected and whether having a biopsy impacts survival. Methods: The medical charts of metastatic breast cancer (MBC) patients diagnosed January 2000-August 2014 were retrospectively reviewed. A biopsy was defined as a procedure where tissue was obtained and assessed for both HR and HER2. Both bivariate and multivariate analyses were performed to assess patient characteristics related to biopsy and whether having a biopsy was associated with improved survival. Results: Of ...
Liver is the organ responsible for hematopoiesis during fetal life, which is also a target organ of metastasis for several cancers. In order to recognize the hepatic metastatic changes, obtain a...
Quantitative multiplex reverse transcriptase-polymerase chain reaction was developed for the simultaneous detection of multiple-gene expression levels of formalin-fixed, paraffin-embedded breast cancer samples. Candidate genes were selected from previous microarray data relevant to breast cancer markers that had the potential to serve as predictive markers for metastatic risk. This multiplex gene set included 11 candidate and 3 housekeeping genes, and the aim was to predict breast cancer progression based on lymph node involvement status.
We report a comprehensive analysis of breast cancer metastases by analyzing the full spectrum of metastatic lesions derived from 10 patients who died of metastatic breast cancer and underwent rapid autopsy. By comparing the primary neoplasms from these patients with their metastases and by comparing metastases from one site to another, we identified marked heterogeneity among breast cancer metastases, as well as markers which remained consistent among these lesions. Our results expand the existing body of knowledge regarding breast cancer metastases and have both biological and therapeutic implications.. With regard to distribution of metastases, we confirm the liver, bone, and lung as the most frequent sites of hematogenous dissemination. We also confirm the striking tendency of lobular carcinoma to metastasize to the gastrointestinal tract, as illustrated by cases MBC1 and MBC5. Case MBC5 is particularly instructive, as the invasive ductal carcinoma primary lost E-cadherin expression in most ...
We have investigated the antitumor effects of synthetic MMP inhibitor MMI270 against postoperative lung metastasis from colon cancer in nude rat. The KM12SM human colon cancer cells were injected into the cecal wall, and at 5 weeks after the injection, the cecum was removed including the tumor. Then, 30 mg/kg of MMI270 was administered perorally twice per day for 2 or 4 weeks, either immediately after removal or after week 2 after the removal. At week 7 after the removal, lung metastasis was significantly inhibited by the early administration of MMI270 immediately after the tumor removal but not by the late administration. The survival rates were significantly higher in the rats treated by early administration of MMI270 compared to the survival rate in untreated rats. Moreover, no lung metastasis was detected in some rats with 24-weeks survival treated by early administration. Lower microvessel density, lower PCNA Index and higher Apoptotic Index in the lung metastases of the rats treated with MMI270
UNLABELLED: Metastatic spread of cancer cells to the brain is associated with high mortality, primarily because current diagnostic tools identify only well-advanced metastases. Brain metastases have been shown to induce a robust glial response, including both astrocyte and microglial activation. On the basis of these findings, we hypothesized that this stromal response may provide a sensitive biomarker of tumor burden, in particular through the use of SPECT/PET imaging agents targeting the translocator protein (TSPO) that is upregulated on activated glia. Our goals, therefore, were first to determine the spatial and temporal profile of glial activation during early metastasis growth in vivo and second to assess the potential of the radiolabeled TSPO ligand (123)I-DPA-713 for early detection of brain metastases. METHODS: Metastatic mouse mammary carcinoma 4T1-green fluorescent protein cells were injected either intracerebrally or intracardially into female BALB/c mice to induce brain metastases.
Breast cancer cells with stem cell properties are key contributors to metastatic disease, and there remains a need to better understand and target these cells in human cancers. Here, we identified rare stem-like cells in patients tumors characterized by low levels of the proapoptotic molecule p53-upregulated modulator of apoptosis (PUMA) and showed that these cells play a critical role in tumor progression that is independent of clinical subtype. A signaling axis consisting of the integrin αvβ3, Src kinase, and the transcription factor Slug suppresses PUMA in these cells, promoting tumor stemness. We showed that genetic or pharmacological disruption of αvβ3/Src signaling drives PUMA expression, specifically depleting these stem-like tumor cells; increases their sensitivity to apoptosis; and reduces pulmonary metastasis, with no effect on primary tumor growth. Taken together, these findings point to PUMA as a key vulnerability of stem-like cells and suggest that pharmacological upregulation ...
Breast cancer cells with stem cell properties are key contributors to metastatic disease, and there remains a need to better understand and target these cells in human cancers. Here, we identified rare stem-like cells in patients tumors characterized by low levels of the proapoptotic molecule p53-upregulated modulator of apoptosis (PUMA) and showed that these cells play a critical role in tumor progression that is independent of clinical subtype. A signaling axis consisting of the integrin αvβ3, Src kinase, and the transcription factor Slug suppresses PUMA in these cells, promoting tumor stemness. We showed that genetic or pharmacological disruption of αvβ3/Src signaling drives PUMA expression, specifically depleting these stem-like tumor cells; increases their sensitivity to apoptosis; and reduces pulmonary metastasis, with no effect on primary tumor growth. Taken together, these findings point to PUMA as a key vulnerability of stem-like cells and suggest that pharmacological upregulation ...
The number of clinicians whose eyes glaze over as metastasis researchers dutifully recite the many steps of the metastatic process, and go on to examine tumor cell invasion in minute detail, signals either that we give boring lectures or that we have evoked the so what? response. Those who would favor the latter response might state that, even for the greater than 90% of patients without detectable distant metastases at surgery, it remains possible that tumor cells have already invaded out of the primary tumor and are sitting contentedly in distant sites undetected. Only growth and angiogenesis remain. Why study metastasis when it may be virtually complete by the time the patient walks into the clinic? Has the barn door been left open? Should we all drop our experiments and switch to antiangiogenesis projects?. Two reviews in this series have addressed this critical question, and arrived at similar answers. Investigators from Dr Ann Chambers laboratory have watched it all happen. She and ...
Cancer is a disease of cell growth, but most tumors only become lethal once they metastasize or spread from their first location to sites throughout the body. For the first time, researchers at Thomas Jefferson University in Philadelphia report a single molecule that appears to be the central regulator driving metastasis in prostate cancer. The study, published online July 13th in Cancer Cell, offers a target for the development of a drug that could prevent metastasis in prostate cancer, and possibly other cancers as well.. Finding a way to halt or prevent cancer metastasis has proven elusive. We discovered that a molecule called DNA-PKcs could give us a means of knocking out major pathways that control metastasis before it begins, says Karen Knudsen, Ph.D., Director of the Sidney Kimmel Cancer Center at Thomas Jefferson University, the Hilary Koprowski Professor and Chair of Cancer Biology, Professor of Urology, Radiation Oncology, and Medical Oncology at Jefferson.. Metastasis is thought of ...
Breast cancer (BCa) remains as the second leading cause of cancer-related death in women worldwide. The majority of the deaths are due to its progression to metastatic BCa. Although Grb2-associated binding protein 1 (Gab1) has been implicated in tumor proliferation and metastasis in multiple tumors including colorectal cancer, hepatocellular carcinoma and ovarian cancer, whether and how it regulates BCa metastasis are still poorly understood. Western blot assay and immunohistochemical (IHC) staining were performed to assess expression of Gab1 in primary and metastatic BCa clinical samples. Biological function assay studies in vitro and in vivo were employed to investigate the functions of Gab1 during BCa metastasis. Co-immunoprecipitation (co-IP) assessment, western blot assay and immunofluorescence (IF) staining were carried out to investigate the underlying mechanism for the function of Gab1 on BCa metastasis. In this study, we found that expression level of Gab1 was increased significantly in BCa
SENP3 promotes gastric cancer cell metastasis in vivo(A) The efficiency of SENP3 overexpression in SGC7901-SENP3 cells used for tumorigenesis in nude mice. (B)
Background Metastasis is the most frequent cause of treatment failure and death in colorectal cancer. Early detection of tumors and metastases is crucial for improving treatment strategies and patient outcome. Development of reliable biomarkers and simple tests routinely applicable in the clinic for detection, prognostication, and therapy monitoring is of special interest. We recently identified the novel gene Metastasis-Associated in Colon Cancer 1 (MACC1), a key regulator of the HGF/Met-pathway. MACC1 is a strong prognostic biomarker for colon cancer metastasis and allows identification of high-risk subjects in early stages, when determined in patients primary tumors. To overcome the limitation of a restricted number of molecular analyses in tumor tissue, the establishment of a non-invasive blood test for early identification of high-risk cancer patients, for monitoring disease course and therapy response is strongly needed. Methodology/Principal Findings For the first time, we describe a non
Previously, we showed that a chemokine CCL2 recruits IMs to metastatic sites where they differentiate to MAMs (Qian et al., 2011). In this study, we revealed a novel role for CCL2 as a trigger of a prometastatic chemokine cascade involving CCL3 signaling via CCR1 that is required for efficient metastasis. These data illustrate a signaling relay that amplifies the pathology already in the system by promoting retention of recruited monocytes that stimulate tumor cell establishment at the metastatic site.. Our in vivo and in vitro results indicate that CCL2 can increase CCL3 expression in MAMs at the metastasis site. The CCL2-induced CCL3 expression is likely to be specific to the prometastatic macrophage lineage, as neutralization of CCL2 by antibodies significantly reduced Ccl3 expression in IMs and MAMs, but not in resident monocytes or macrophages. Consistent with this interpretation, expression of Ccl3 was highest in MAMs compared with other leukocytes in the tumor-bearing lung. Importantly, a ...
Fingerprint Dive into the research topics of Enhanced metastatic potential of tumor cells harvested from spontaneous metastases of heterogeneous murine tumors. Together they form a unique fingerprint. ...
Gastric cancer (GC) is one of the common reasons of cancer-related death with few biomarkers for diagnosis and prognosis. Solute carrier family 2 (facilitated glucose transporter) member 1 protein SLC2A1, also known as glucose transporter type 1 (GLUT1), has been associated with tumor progression, metastasis, and poor prognosis in many human solid tumors. However, little is reported about its clinical significance and biological functions in GC. Here we observed a strong up-regulation of SLC2A1 in patients with GC and found that SLC2A1 was significantly correlated with depth of invasion and clinical stage. Additionally, over-expression of SLC2A1 in GC cells promotes cellular proliferation and metastasis in vitro and enhances tumor growth in vivo as well as enhancement of glucose utilization. Meanwhile, elevated SLC2A1 also contributes to tumor metastasis in vitro. Our results indicate SLC2A1 exhibits a pivotal role in tumor growth, metastasis and glucose metabolism, and also suggest SLC2A1 as a
A role for bone marrow-derived cells (BMDCs) in promoting metastatic tumor growth is emerging, with important implications for therapeutic strategies to decrease tumor metastases. While previous work has shown accumulation of CD11b+ BMDCs in the lungs of mice bearing metastatic breast tumors, questions remain about the precise identity of these cells, the factors that regulate CD11b+ cell accumulation, and the potential long-term influence of CD11b+ cells on metastatic growth. We used transplantable (4T1, 4TO7, 67NR) and spontaneous (polyomavirus middle-T; PyVmT) mammary tumor models to study the identity, induction, longevity, and function of CD11b+ BMDCs in tissues. Using flow cytometry and ex vivo immune suppression assays, we established that metastatic mammary tumors induce splenic expansion and pulmonary accumulation of functional CD11b+Gr1+ myeloid-derived suppressor cells (MDSCs) and CD11b+F4/80+ macrophages (Mϕs). MDSCs suppress T cell-mediated immune responses against tumor cells and ...
Next, they found that the Skp2 overexpression also results in more RhoA, and that both Skp2 and Myc were required for the metastasis-producing RhoA to be overexpressed. This cancer-promoting pathway is the second way Skp2 fuels cancer growth, Lin said. Skp2 has been shown to work through a separate E3 ligase pathway to destroy tumor-suppressing proteins, causing heightened cellular proliferation and the transition from normal cell to tumor.. Skp2s E3 ligase activity is required for tumorigenesis, but not involved at all in metastasis, Lin said. Lin and colleagues also previously found that Skp2 blocks cellular senescence - a halt in cell division - in cancer cells.. The research team then found that Skp2 recruits two other proteins, p300 and Miz1, to join Myc and form the complex that transcribes RhoA. Experiments in a mouse model of breast cancer metastasis to the lung showed that deficiency of either Myc, Skp2 or Miz1 restricted metastasis, while overexpression of each of the three proteins ...
Read about how researchers discovered that a densely packed tumor environment triggers cancer spread by switching on metastasis genes.
Free Online Library: New candidate drug stops cancer metastasis and regenerates nerve cells. by Asian News International; News, opinion and commentary General interest Cancer Care and treatment Drug therapy Cancer metastasis Cancer treatment G proteins Metastasis Neurons
Many cancer cell types, as well as their metastases, express high levels of CD44. Whereas some tumors, such as gliomas, exclusively display CD44s, other neoplasms, including brain metastases, gastrointestinal cancer, pancreatic adenocarcinoma, bladder cancer, uterine cervical cancer, breast cancer and non-Hodgkins lymphomas, additionally and sometimes preferentially express CD44 variants. Hence, CD44, particularly its variants, may be used as diagnostic or prognostic markers of at least some human malignant diseases. Furthermore, it has been demonstrated in animal models that upon transfection with CD44s, or CD44v cDNA, nonmetastatic tumor cells acquire metastatic potential. In addition, injection of reagents interfering with CD44-ligand interaction (e.g. CD44s- or CD44v-specific mAb) inhibit local tumor growth and metastatic spread in murine species. In this context, CD44 may confer a growth advantage on some neoplastic cells, and consequently could be used as a target for cancer therapy. The ...
A chip developed by mechanical engineers at Worcester Polytechnic Institute (WPI) can trap and identify metastatic cancer cells in a small amount of blood drawn from a cancer patient. The breakthrough technology uses a simple ...
Côté and his team have recently demonstrated that there is a protein - AXL, that influences metastasis in HER2-positive cancer. Cells that have high levels of AXL have more chances to detach from the tumor and cause metastases.. The study was conducted on mice with samples of tumor cells from patients with cancer. But even with no study on mice, statistics show that women with less AXL present have a better chance of survival.. Based on this discovery, a treatment targeting AXL could reduce the risk of metastasis, explains Côté.. There is a drug therapy that inhibits AXL, and the IRCM researchers have administered it to mice used in their study. They discovered that metastases were less likely to develop. At the moment, the drug is tested in different therapies, and if future tests are successful, this drug could treat patients with breast cancer, complementing the treatments that focus on the tumor.. Côté added that he and his team are still working in the lab:. At the moment, we are ...
Cancer is a heterogeneous disease of rapidly dividing cells with multiple mechanisms of survival. In one such survival mechanism, cancerous cells metastasize to a location distal from the original tumor. The complex process of metastasis often requires a cell to undergo multiple transformative events. First, a cancerous cell must break down the extracellular matrix and break contacts with adjacent cells to migrate from the original tumor through a blood or lymphatic vessel wall. The cancerous cell then circulates through the bloodstream, adheres to the vessel wall at a distal location, and migrates through the blood vessel again. Ultimately, the metastatic cell establishes a new site for growth, forming a secondary tumor. Tumor metastases are typically found first in the lymph nodes near the primary tumor, and only later at other distal locations. Metastatic tumors often prove difficult to treat because they may continually metastasize to multiple locations. New metastatic mechanisms are ...
Cancer is a heterogeneous disease of rapidly dividing cells with multiple mechanisms of survival. In one such survival mechanism, cancerous cells metastasize to a location distal from the original tumor. The complex process of metastasis often requires a cell to undergo multiple transformative events. First, a cancerous cell must break down the extracellular matrix and break contacts with adjacent cells to migrate from the original tumor through a blood or lymphatic vessel wall. The cancerous cell then circulates through the bloodstream, adheres to the vessel wall at a distal location, and migrates through the blood vessel again. Ultimately, the metastatic cell establishes a new site for growth, forming a secondary tumor. Tumor metastases are typically found first in the lymph nodes near the primary tumor, and only later at other distal locations. Metastatic tumors often prove difficult to treat because they may continually metastasize to multiple locations. New metastatic mechanisms are ...
This increased metastatic cell line was derived using an in vivo selection process of highly metastatic cells from a population of poorly metastatic tumor cells, A375  (ATCC CRL-1619). The A375-M1 (ATCC CRL-3222) cell line was derived by i.v. injection of A375 cells into nude mice. Lung metastases were harvested and amplified in vitro as cell lines. The A375-M1 cell line was reinjected into mice for a second round of selection, lung metastases harvested and amplified in vitro as A375-M2 (ATCC CRL-3223) cells. The A375-M1 and A375-M2 cell lines were  transfected with a plasmid containing the ecotropic receptor for murine retrovirus and selected for neomycin resistance. This is useful for RNAse protection assays.
Bone metastases from breast cancer are common, causing significant morbidity. Preclinical data of dasatinib, an oral small molecule inhibitor of multiple oncogenic tyrosine kinases, suggested...
Metastasis causes the death of patients with solid cancers. The core molecular mechanism of metastasis remains largely unknown. The research of Dr. Zhang John Weihuas laboratory focuses on understanding the following metastasis-related molecular mechanisms:. 1. The tyrosine kinase independent function of the epidermal growth factor receptor, EGFR.. 2. The impact of organ microenvironment on the energy metabolism of cancer metastasis.. 3. The role of intracellular ATP levels of cancer cells in the development of cancer metastasis.. ...
Metastases, or secondary tumours, cause around 90 per cent of all deaths from cancer. The ability to gain knowledge as soon as possible about the cancer cells tendency to spread and form metastases could save many lives.. The Cellrace research is based on studies of a biopsy on a specially designed nanosurface.. It is not possible to study the cells movements and behaviour on a microscope slide, as that is not their natural environment. On our nanosurface, we have imitated critical properties from the environment in which they usually operate, i.e. in the body. There we can study them in real time, says Michael Andäng.. At present there is a prototype and the researchers have been able to show statistically significant differences between metastasising cells and non-metastasising cells.. Now we are refining the product and preparing to collaborate with clinics. For example, we want to repeat the tests with recently obtained biopsies. ...
The second major focus of our research is the spread of cancer from its initial site of growth to other locations in the body (metastasis), which is a major factor influencing the likelihood of successful treatment. The formation of metastasis by tumour cells is thought to be dependent on the expression of specific phenotypes by individual tumour cells. Our research is examining metastatic phenotypes that are expressed only transiently and that may be induced by exposure of tumour cells to conditions, such as hypoxia, which occur in the tumour microenvironment. Recent clinical results have suggested that tumours that contain substantial hypoxic regions may be more likely to form metastases. We have found in animal model systems that exposure to hypoxia, both in vitro and in vivo, can cause transient increases in the metastatic potential of tumour cells and that exposure to transient hypoxic episodes may be particularly important for this increased metastatic potential. We are examining the ...
Colon cancer is one of the most frequent malignant diseases worldwide. About 50% of the patients develop distant metastasis. These patients have only few therapy options and very poor survival rates. Therefore cancer research focuses on the identification of novel molecular markers to provide a better prognosis of the metastatic risk. Identified high-risk patients would get access to an early, individualized therapy. MACC1 (metastasis associated in colon cancer 1) is a newly identified gene that is overexpressed in colon carcinomas and their distant metastases. The MACC1 domain structure is characteristic for proteins of the receptor tyrosine kinase signalling pathways. Aim of this study was the analysis of the cellular function of MACC1, its role in tumor progression and its evaluation as a molecular, prognostic marker for metastasis. MACC1 overexpressing tumor cells revealed higher migratory, invasive, and proliferative potential in in vitro assays. The impact of MACC1 on the metastatic ...
Endpoints:. - Response Rate, Disease control rate, The duration of overall response, Overall survival, PFS, Time to treatment failure, Quality of Life, Incidence of AEs, Frequency and nature of serious adverse reactions (SADRs), Premature withdrawals. Statistical methods:. Assuming a randomization ratio of 1:1, 282 deaths are required in order to achieve a power of 80% of detecting a hazard ratio of 0.72 in favour of one of the two sequences, translating in an increase of median survival time from 10 to 14 months, with a type I error of 5%, two-sided, using the Mantel-Cox version of the log-rank test. With a uniform accrual period of 3 years and a follow-up of 18 months, about 350 patients will be needed to reach the target number of events.. All statistical analyses will be based on an intention-to-treat approach. CONSORT rules will be applied to describe study flow and protocol deviations.. All OS and PFS curves will be drawn with the Kaplan-Meier method. Results will be presented as Hazard ...
Oligometastatic prostate cancer has been considered an intermediate state between localized disease and widespread metastases, but there is no
The most widely used staging system for colorectal cancer is the AJCC tumor, nodes, metastasis (TNM) classification system, which classifies patients into prognostic groups according to the depth of the primary tumor, presence of regional LN metastases, and evidence of distant metastases. Recently, the AJCC TNM stage was updated and the T and N stages were further specified to improve prognostic capacity. More emphasis has been made to the number of retrieved malignant LNs. Accordingly, pN1 (metastasis in 1 to 3 regional LNs) has been subdivided into pN1a (metastasis in 1 regional LN) and pN1b (metastasis in 2 to 3 regional LNs), and pN2 (metastasis in 4 or more regional LNs) has been subdivided into pN2a (metastasis in 4 to 6 regional LNs) and pN2b (metastasis in 7 or more regional LNs).11. However, the number of malignant LNs in rectal cancer depends on the number of retrieved LNs, which varies with treatment, patient, and tumor characteristics. There is, in practice, wide variation in the ...
BARCELONA - It is clinically feasible to measure breast tumor cells in a patients circulation, according to the findings of an observational study.. The next step is to determine whether the presence of these cells is truly predictive of impending recurrence or metastasis.. Breast cancer kills only if it metastasizes, so it is important to identify the earliest signs of metastasis. Measuring circulating tumor cells (CTCs) may be a key step in this direction, said Dr. Julia Jueckstock of the department of obstetrics and gynecology, Ludwig-Maximilians University, Munich, where the technique is being pioneered.. Earlier findings showing that CTCs can be measured in bone marrow samples suggest that the presence of tumor cells outside the primary tumor site are indeed predictive of metastasis and poor prognosis. But the difficulty of obtaining bone marrow makes this approach impractical for routine clinical use. Analysis of peripheral blood is potentially much more useful.. Dr. Jueckstock and her ...
SCC-S2/GG2-1/NDED (approved gene symbol TNFAIP8) is a transcription factor NF-kappaB-inducible, antiapoptotic, and oncogenic molecule. In this study, we examined the role of SCC-S2 in invasion and experimental metastasis. We demonstrate that expression of SCC-S2 cDNA in MDA-MB 435 human breast cance …
Find helpful learner reviews, feedback, and ratings for Understanding Cancer Metastasis from 존스홉킨스대학교. Read stories and highlights from Coursera learners who completed Understanding Cancer Metastasis and wanted to share their experience. A big thanks to John Hopkins University for this course the faculty of this university is one of the...
PRIMARY OBJECTIVES:. I. To determine whether every-12-week therapy with zoledronic acid is not inferior to every-4-week therapy for patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma involving bone, as measured by the proportion who experience at least one skeletal related event within 24 months after randomization.. SECONDARY OBJECTIVES:. I. To compare pain scores (Brief Pain Inventory) of patients with metastatic breast cancer, metastatic prostate cancer, or myeloma involving bone receiving every 12 week dosing of zoledronic acid to those receiving every 4 week dosing.. II. To compare the functional status (Eastern Cooperative Oncology Group [ECOG] performance status) of patients with metastatic breast cancer, metastatic prostate cancer, or myeloma involving bone receiving every 12 week dosing of zoledronic acid to those receiving every 4 week dosing.. III. To compare the incidence of osteonecrosis of the jaw in patients with metastatic breast cancer, ...
TY - JOUR. T1 - Enhanced Metastatic Recurrence Via Lymphatic Trafficking of a High-Metastatic Variant of Human Triple-Negative Breast Cancer After Surgical Resection in Orthotopic Nude Mouse Models. AU - Yano, Shuuya. AU - Takehara, Kiyoto. AU - Tazawa, Hiroshi. AU - Kishimoto, Hiroyuki. AU - Kagawa, Shunsuke. AU - Bouvet, Michael. AU - Fujiwara, Toshiyoshi. AU - Hoffman, Robert M.. PY - 2017/3/1. Y1 - 2017/3/1. N2 - We previously developed and characterized a highly invasive and metastatic triple-negative breast cancer (TNBC) variant by serial orthotopic implantation of MDA-MB-231 human breast cancer cells in nude mice. Eventually, a highly invasive and metastatic variant of human TNBC was isolated after lymph node metastases was harvested and orthotopically re-implanted into the mammary gland of nude mice for two cycles. The variant thereby isolated is highly invasive in the mammary gland and metastasized to lymph nodes in 10 of 12 mice compared to 2 of 12 of the parental cell line. In the ...
Metastatic breast cancer, also referred to as metastases, advanced breast cancer, secondary tumours, secondaries or stage 4 breast cancer, is a stage of breast cancer where the disease has spread to distant sites beyond the axillary lymph nodes. There is no cure for metastatic breast cancer. There is no stage after IV. It usually occurs several years after the primary breast cancer, although it is sometimes diagnosed at the same time as the primary breast cancer or, rarely, before the primary breast cancer has been diagnosed. Metastatic breast cancer cells frequently differ from the preceding primary breast cancer in properties such as receptor status. The cells have often developed resistance to several lines of previous treatment and have acquired special properties that permit them to metastasize to distant sites. Metastatic breast cancer can be treated, sometimes for many years, but it cannot be cured. Distant metastases are the cause of about 90% of deaths due to breast cancer. Breast ...
Purpose Reports have suggested that metastatic site is an important predictor of overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), but these were based on a limited number of patients. We investigate the impact of site of metastases on OS of a substantial sample of men with mCRPC who received docetaxel chemotherapy in nine phase III trials. Patients and Methods Individual patient data from 8,820 men with mCRPC enrolled onto nine phase III trials were combined. Site of metastases was categorized as lymph node (LN) only, bone with or without LN (with no visceral metastases), any lung metastases (but no liver), and any liver metastases. Results Most patients had bone with or without LN metastases (72.8%), followed by visceral disease (20.8%) and LN-only disease (6.4%). Men with liver metastases had the worst median OS (13.5 months). Although men with lung metastases had better median OS (19.4 months) compared with menwith liver metastases, they had ...
In this article, we report the derivation of highly metastatic human melanoma cell lines from poorly metastatic parental lines using an animal metastasis model. We subsequently identified a metastasis aggressiveness gene signature by comparing the gene expression patterns of tumor samples from the highly metastatic derivatives with those from their parental lines. By comparisons with gene expression data from human clinical samples, we found that expression of this metastasis gene signature in human melanoma metastases correlates with poor survival of the corresponding patients. The signature is able to segregate melanoma-bearing patients into three groups, one of which has a significantly lower survival probability. This suggests that the signature provides an indication of aggressiveness of the melanoma metastases rather than of metastasis per se, similar to the lung metastasis signature reported by Minn et al. (10). This result has been confirmed by alternative methods such as GSEA and ...
Apart from the breast tumor cells, the resident stromal cells also contribute to tumor survival. Links to carefully selected news and features about metastatic breast cancer research. Metastatic breast cancer occurs when the cancer spreads from the breast to another part of the body. Taking breaks in treatment when the disease is under control and you are feeling good can make a big difference in your quality of life. [23] In women with metastatic breast cancer who do not have triple negative disease, there is little or no survival benefit and excess toxicity from platinum-based regimens. You dont have to go through metastatic breast cancer alone. Integrin-mediated tumor cell adhesion to ECM proteins can trigger signal transduction and cause upregulation of gene expression, increased tyrosine phosphorylytion of the focal adhesion kinase, and activation and nuclear translocation of mitogen-activated protein (MAP) kinases. Sometimes when people are diagnosed with metastatic cancer, doctors Its
Metastasis is a major clinical challenge for cancer treatment. Emerging evidence suggests that aberrant epigenetic modifications contribute significantly to tumor formation and progression. However, the drivers and roles of such epigenetic changes in tumor metastasis are still poorly understood. Using bioinformatic analysis of human breast cancer gene-expression data sets, we identified histone demethylase RBP2 as a putative mediator of metastatic progression. By using both human breast cancer cells and genetically engineered mice, we demonstrated that RBP2 is critical for breast cancer metastasis to the lung in multiple in vivo models. Mechanistically, RBP2 promotes metastasis as a pleiotropic positive regulator of many metastasis genes, including TNC. In addition, RBP2 loss suppresses tumor formation in MMTV-neu transgenic mice. These results suggest that therapeutic targeting of RBP2 is a potential strategy for inhibition of tumor progression and metastasis. ...
Accumulated evidence shows that many cancers including prostate cancer disseminate to metastatic sites early in the natural history of disease and can remain undetected and quiescent for extended periods of time.3, 4, 10 In one recent report, disseminated prostate cancer cells (DTCs) can be detected in the bone marrow of 57% men who are without evidence of disease after prostatectomy. With a median follow-up of 42 months, 52% of those with DTCs have not recurred, including patients who still have DTCs 12 years after surgery.5 Thus, in the context of prostate cancer recurrence, metastatic colonization, or the progressive outgrowth of disseminated cancer cells within a secondary site into clinically manifested metastases, is a particularly critical aspect to the multistep metastatic process.7, 35 The molecular factors that control the survival and eventual growth of these disseminated cells are largely unknown.. Experimental modulation of metastasis suppressor genes preclinically affords the ...
TY - JOUR. T1 - Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic acid-induced 2. AU - Werner, Stefan. AU - Brors, Benedikt. AU - Eick, Julia. AU - Marques, Elsa. AU - Pogenberg, Vivian. AU - Parret, Annabel. AU - Kemming, Dirk. AU - Wood, Antony W.. AU - Edgren, Henrik. AU - Neubauer, Hans. AU - Streichert, Thomas. AU - Riethdorf, Sabine. AU - Bedi, Upasana. AU - Baccelli, Irene. AU - Jucker, Manfred. AU - Eils, Roland. AU - Fehm, Tanja. AU - Trumpp, Andreas. AU - Johnsen, Steven. AU - Klefstrom, Juha. AU - Wilmanns, Matthias. AU - Muller, Volkmar. AU - Pantel, Klaus. AU - Wikman, Harriet. PY - 2015/5/1. Y1 - 2015/5/1. N2 - Regulatory pathways that drive early hematogenous dissemination of tumor cells are insufficiently defined. Here, we used the presence of disseminated tumor cells (DTC) in the bone marrow to define patients with early disseminated breast cancer and identified low retinoic acid-induced 2 (RAI2) expression to be ...
Dissemination of breast cancers to the brain is associated with poor patient outcome and limited therapeutic options. In this study we sought to identify novel regulators of brain metastasis by profiling mouse mammary carcinoma cells spontaneously metastasising from the primary tumour in an immunocompetent syngeneic host. 4T1 mouse mammary carcinoma sublines derived from primary tumours and spontaneous brain and lung metastases in BALB/c mice were subject to genome-wide expression profiling. Two differentially expressed genes, Id2 and Aldh3a1, were validated in in-vivo models using mouse and human cancer cell lines. Clinical relevance was investigated in datasets of breast cancer patients with regards to distant metastasis-free survival and brain metastasis relapse-free survival. The role of bone morphogenetic protein (BMP)7 in regulating Id2 expression and promoting cell survival was investigated in two-dimensional and three-dimensional in-vitro assays. In the spontaneous metastasis model, expression
To understand colon cancer metastasis, we earlier analyzed a mouse model that developed liver metastasis of cancer cells disseminated from the spleen. We suggested that CCR1(+) bone marrow (BM)-derived cells are recruited to the microenvironment of disseminated colon cancer cells, and produce metall …
A systematic comparison of metastatic breast cancer cells to healthy breast cells revealed dramatic differences between the two cell lines in their mechanics, migration, oxygen response, protein production, and ability to stick to surfaces.. The new study details how cells make the transition from nonmalignant to metastatic, a process that is not well understood.. By bringing together different types of experimental expertise to systematically compare metastatic and nonmetastatic cells, we have advanced our knowledge of how metastasis occurs, says Robert Austin, professor of physics at Princeton University.. The study also found that metastatic cells recover more rapidly from the stress of a low-oxygen environment than nonmetastatic cells, which is consistent with previous studies. Although the low-oxygen environment did kill many of the metastatic cells, the survivors rebounded vigorously, underscoring the likely role of individual cells in the spread of ...
Breast cancer metastatic mouse models are experimental approaches in which mice are genetically manipulated to develop a mammary tumor leading to distant focal lesions of mammary epithelium . Recent ameliorations in maneuvering the mouse genome have provided the technology to induce mammary cancers in mice arising from genetic mutations that have been identified in human cancer. This means models can be generated based upon molecular lesions consistent with the human disease. Metastasis is a process of migration of tumour cells from the primary cancer site to a distant location where the cancer cells form secondary tumors. Metastatic breast cancer represents the most devastating attribute of cancer and it is considered an advanced-stage event. Human breast cancer metastasizes to multiple distant organs such as the brain, lungs, bones and liver. The classical theory developed in the early 70s anticipated that metastasis is due to genetically determined subpopulations in primary tumours. The ...
Due to the effi cient screening and early detection most breast cancer cases are recognized today in early stage. Approximately 5% of newly detected cases have distant metastasis. In Hungary the situation is worse. Early stage disease will relapse in about 30%, mainly with distant metastasis. Metastatic breast cancer is incurable disease, except some rare, special cases. As systemic therapeutic options are developing rapidly, most breast cancer subtypes can be treated successfully and long term survival is not rare. Primary objective of the treatment is increasing overall survival and quality of life, by decreasing disease related symptoms. In this review we summarize the systemic therapeutic options of metastatic breast cancer according to the subtypes. It is recommended to use an individual treatment plan for every patient.. ...
Most ovarian cancer patients present with disseminated disease at the time of their diagnosis, which is one of the main reasons for their poor prognosis. Metastasis is a multi-step process and a clear understanding of the mechanism of regulation of these steps remains elusive. Productive reciprocal interactions between the metastasizing ovarian cancer cells and the microenvironment of the metastatic site or the tumor microenvironment play an important role in the successful establishment of metastasis. Much progress has been made in the recent past in our understanding of such interactions and the role of the cellular and acellular components of the microenvironment in establishing the metastatic tumors. This review will outline the role of the microenvironmental components of the ovarian cancer metastatic niche and their role in helping establish the metastatic tumors. Special emphasis will be given to the mesothelial cells, which are the first cells encountered by the cancer cells at the site of
Jill Cohen, on living with stage IV breast cancer for 13 years. Learn more about metastatic breast cancer and support the Beyond the Breast Campaign.In August I celebrated 13 years of living with metastatic breast cancer. Yes, I celebrated - wouldnt you? I called it my
Metastasis is the major cause of treatment failure in cancer patients and of cancer-related deaths. This editorial discusses how cancer metastasis may be better perceived and controlled. Based on big-data analyses, a collection of 150 important pro-metastatic genes was studied. Using The Cancer Genome Atlas datasets to re-analyze the effect of some previously reported metastatic genes-e.g., JAM2, PPARGC1A, SIK2, and TRAF6-on overall survival of patients with renal and liver cancers, we found that these genes are actually protective factors for patients with cancer. The role of epithelial-mesenchymal transition (EMT) in single-cell metastasis has been well-documented. However, in metastasis caused by cancer cell clusters, EMT may not be necessary. A novel role of epithelial marker E-cadherin, as a sensitizer for chemoresistant prostate cancer cells by inhibiting Notch signaling, has been found. This editorial also discusses the obstacles for developing anti-metastatic drugs, including the lack of high
Establishment of skeletal metastasis involves bidirectional interactions between the tumor cell and the cellular elements in the bone microenvironment. A better understanding of the pathophysiology of bone metastasis will be critical in developing the means to prevent bone metastasis or inhibit its progression. The receptor activator of nuclear factor-κB (RANK)/RANK ligand pathway has emerged as the key pathway regulating osteolysis in skeletal metastasis. A number of candidate factors, including the Wnt (wingless int) proteins, endothelin-1, and bone morphogenetic proteins, have been implicated in the establishment of osteoblastic metastasis. The complex nature of tumor-bone microenvironment interactions and the presence of multiple pathways that lead to bone metastasis suggests that simultaneous targeting of these pathways in the metastatic cascade are required for effective treatment. This review discusses current understanding of the pathophysiologic mechanisms that underlie the establishment of
Sunitinib is a potent and clinically approved tyrosine kinase inhibitor that can suppress tumour growth by inhibiting angiogenesis. However, conflicting data exist regarding the effects of this drug on the growth of metastases in preclinical models. Here we use 4T1 and RENCA tumour cells, which both form lung metastases in Balb/c mice, to re-address the effects of sunitinib on the progression of metastatic disease in mice. We show that treatment of mice with sunitinib prior to intravenous injection of tumour cells can promote the seeding and growth of 4T1 lung metastases, but not RENCA lung metastases, showing that this effect is cell line dependent. However, increased metastasis occurred only upon administration of a very high sunitinib dose, but not when lower, clinically relevant doses were used. Mechanistically, high dose sunitinib led to a pericyte depletion effect in the lung vasculature that correlated with increased seeding of metastasis. By administering sunitinib to mice after intravenous
TY - JOUR. T1 - Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells. AU - Terp, Mikkel G. AU - Olesen, Kristina A. AU - Christensen, Eva Arnspang. AU - Lund, Rikke R. AU - Lagerholm, B Christoffer. AU - Ditzel, Henrik J. AU - Leth-Larsen, Rikke. PY - 2013. Y1 - 2013. N2 - Recent studies have shown that Abs that target the cell-surface enzyme CD73 (ecto-5-nucleotidase) reduce growth of primary tumors and metastasis in syngenic mice by inhibiting the catalytic activity of CD73, and thus increasing the activity of cytotoxic T lymphocytes. In this article, we report another anticancer mechanism of anti-CD73 Abs and show that an anti-CD73 mAb (AD2) inhibits metastasis formation by a mechanism independent of CD73 catalytic activity and inhibition of primary tumor growth. This mechanism involves clustering and internalization of CD73, but does not require cross-linking of ...
Cancer cells can break away from where they first formed and travel through the blood or lymph system to form new tumors (metastases) in other parts of the body. Metastases of the lung are tumors in the lung that originated from a primary tumor located in a different part of the body.. Metastatic cancer has the same name as the primary cancer. For example, breast cancer that spreads to the lung is called metastatic breast cancer, not lung cancer. It is treated as a stage IV breast cancer rather than a primary lung cancer. Limited metastases to the lung can be treated with resection or ablation.. ...
On September 28, 2017, the FDA approved abemaciclib (Verzenio; Eli Lilly), a cyclin-dependent kinase (CDK)4/CDK6 inhibitor, in combination with fulvestrant, for the treatment of women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer that progressed after endocrine therapy, and as monotherapy for HR-positive, HER2--negative advanced or metastatic breast cancer that progressed after endocrine therapy and previous chemotherapy in the metastatic setting.
Data presented above show that the human fibrosarcoma cell line HT1080 is able to inhibit the growth of experimental metastases. These results suggest that this inhibition is due to the antiangiogenic activity of circulating TSP-1 that is released by the tumor cells in vivo, circulates at effective levels, and makes the tumor-bearing animals unable to mount an angiogenic response. The data also demonstrate the in vivo efficacy of soluble TSP-1, showing it can be used as a drug to prevent the growth of experimental metastases.. HT1080 produced concomitant tumor resistance directly by secreting active TSP-1, unlike previously studied rodent tumors that create an antiangiogenic state when the tumor cells, or associated stromal elements (29), secrete enzymes or activators of enzymes (30) that generate inhibitors from other molecules. We saw no significant evidence for in vivo breakdown of tumor-derived TSP-1 to fragments smaller than the 140 kDa monomer, a molecule that is as effective an ...
TY - JOUR. T1 - Correction. T2 - De-acetylation and degradation of HSPA5 is critical for E1A metastasis suppression in breast cancer cells [Oncotarget. 5, 21, (2014) (10558-70)] doi: 10.18632/oncotarget.2510.. AU - Chang, Yi Wen. AU - Chen, Hsin An. AU - Tseng, Chi Feng. AU - Hong, Chih Chen. AU - Ma, Jui Ti. AU - Hung, Mien Chie. AU - Wu, Chih Hsiung. AU - Huang, Ming Te. AU - Su, Jen Liang. PY - 2016. Y1 - 2016. N2 - Present: Due to an error made during the assembly of Figure 1A. The data of migration and invasion ability of HS578T groups and HBL100 groups are exist in the same excel file and we misplaced the histogram of HS578T groups as the HBL100 groups histogram, caused the inadvertently duplication during the preparation and assembly of Figure 1A. We apologize for our careless mislabelling and this error has been corrected now. The experimental results and conclusions of this article are not affected by this modification. We deeply regret this error and apologize to the scientific ...
Despite decades of effort, little progress has been made to improve the diagnosis and treatment of cancer metastases. In particular, because of the heterogeneity of cancer and its ability to develop resistance to current treatments that target biochemical markers, new targeting strategies are urgently needed. Inspired by the tight correlation between increases in tissue stiffness and breast cancer metastatic niches found in recent studies (13, 15, 17, 18, 45) and the fact that MSCs differentiate to specific lineages depending on the stiffness of the microenvironment (28), we have developed a class of cancer therapeutics that directly target the mechanoenvironmental cues of cancer metastases. The MRCS is an attempt to directly interrogate the mechano-niche in vivo and apply it for localized delivery of agents including imaging reporters and therapeutics.. Mechano-niches play vital roles in development, homeostasis, and disease progression, including many types of cancer, and therefore serve as an ...
TY - JOUR. T1 - Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. AU - Haeno, Hiroshi. AU - Gonen, Mithat. AU - Davis, Meghan B.. AU - Herman, Joseph M.. AU - Iacobuzio-Donahue, Christine A.. AU - Michor, Franziska. PY - 2012/1/20. Y1 - 2012/1/20. N2 - Pancreatic cancer is a leading cause of cancer-related death, largely due to metastatic dissemination. We investigated pancreatic cancer progression by utilizing a mathematical framework of metastasis formation together with comprehensive data of 228 patients, 101 of whom had autopsies. We found that pancreatic cancer growth is initially exponential. After estimating the rates of pancreatic cancer growth and dissemination, we determined that patients likely harbor metastases at diagnosis and predicted the number and size distribution of metastases as well as patient survival. These findings were validated in an independent database. Finally, we analyzed the effects of different ...
The term metastatic breast cancer means that cancer has spread to organs outside the breast or surrounding lymph nodes, such as the liver, lung, and brain. Metastatic breast cancer is not a curable condition. However, treatment can prolong life, dela
Keywords: LncRNA, FOXF1-AS1, EMT, metastasis, lung cancers Launch As one of the most common causes of cancers related loss of life of the global globe, lung cancers provides become a serious open public wellness issue [1]. Two primary subtypes of lung cancers are called as non-small cell lung cancers (NSCLC) and little cell lung cancers, which accounts for around 80-85% and 15-20% respectively [2]. Although developments in the molecular carcinogenesis and brand-new targeted therapies for NSCLC created significantly in the previous few years [3C5], the general success of sufferers with this disease continues to be low [6 still, 7]. The high fatality is related to early metastasis [8] most likely; nevertheless, the mechanism underlying metastasis is unknown however still. Metastasis of NSCLC is certainly a complicated procedure and modulated by many guidelines [9]. NSCLC cells get away from the principal tumor to a brand-new tissues or body organ when metastasis starts. The primary vital ...
MicroRNA-7 (miR-7) has been observed as a potent tumour suppressor in multiple cancer types including breast cancer. The aim of this study was to investigate th...
Objectives: Breast cancer has been the second most prevalent and fatal malignancy due to its frequent metastasis to other organs. We aim to study the effects of a key miRNA-mRNA signaling in breast cancer.Results: CNN1 was identified as the key gene in breast cancer by the bioinformatics analysis, and the downregulation of CNN1 in breast cancer tissues and cell lines was observed. Upregulating CNN1 inhibited cell survival, migration, invasion, and adhesion, but enhanced cell apoptosis. miR-106b-5p not only bound to CNN1 mRNA 3’UTR, but also promoted lung metastasis in vivo. Besides, the miR-106b-5p mimic enhanced breast cancer canceration by targeting CNN1 and activating Rho/ROCK1 signaling pathway.Conclusion: Overall, our results proved that miR-106b-5p promoted the metastasis of breast cancer by suppressing CNN1 and activating Rho/ROCK1 pathway.Methods: Bioinformatics analysis was performed to select the key gene in breast cancer. The overexpression and knockdown of Calponin 1 (CNN1) in
Tumor cell migration is a key step in the formation of cancer metastasis. The mammalian target of rapamycin (mTOR), a highly conserved and ubiquitously expressed serinethreonine kinase, has been intensely studied for over a decade as a central regulator of cell growth, proliferation, differentiation, and survival. Recent data have shown that mTOR also plays a critical role in the regulation of tumor cell motility and cancer metastasis. Here, we briefly review recent advances regarding mTOR signaling in tumor cell motility. We also discuss recent findings about the mechanism by which rapamycin, a specific inhibitor of mTOR, inhibits cell motility in vitro and metastasis in vivo.. ...
ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO or via grants from the sponsors and supporters.. Via L. Taddei 4, 6962 Viganello - Lugano - CH © Copyright 2017 European Society for Medical Oncology All rights reserved worldwide.. ...
Bone metastasis is a common event in advanced cancers such as prostate, breast, lung, and renal cancers. Radiation therapy has been widely used for bone metastasis. However, it remains a challenging therapy because no radiation therapeutic guidelines, including radiation dose, radiation field, and fractionation, for patients with bone metastasis have been established. Many randomized controlled trials for bone metastasis have been carried out. They showed no significant difference in pain relief with a short course of radiation therapy such as 8 Gy/1 Fr and 20 Gy/5 Fr or with a long course of radiation therapy such as 30 Gy/10 Fr, 37.5 Gy/15 Fr, and 40 Gy/20 Fr. Toxicity rates with short and long courses were also the same. Recurrence rate at 2 years, however, was significantly higher in patients irradiated with a short course than in patients irradiated with a long course. Those trials also showed that response rate is affected by patients age, performance state, tumor type, pathological state, number
article: A rare case of metastatic deposits of cervical carcinoma in the heart - Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2019 March;178(3):154-6 - Minerva Medica - Riviste
The establishment of distant metastases depends on the capacity of small numbers of cancer cells to regenerate a tumor after entering a target tissue. The mechanisms that confer this capacity remain to be defined. Here we identify a role for the transcriptional inhibitors of differentiation Id1 and Id3 as selective mediators of lung metastatic colonization in the triple negative [TN, i.e., lacking expression of estrogen receptor and progesterone receptor, and lacking Her2 (human epidermal growth factor receptor 2) amplification] subgroup of human breast cancer. Although broad expression of Id1 has recently been documented in tumors of the rare metaplastic subtype, here we report that rare Id1-expressing cells are also present in the more common TN subset of human breast tumors but not in other subtypes. We also provide evidence that Id1 expression is enriched in clinically obtained hormone receptor negative lung metastases. Functional studies demonstrate that Id1 and its closely related family ...
Study of MK-1454 Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced / Metastatic Solid Tumors or Lymphomas (MK-1454-001) - NCT03010176
Of the nine patients in the UCLA study who underwent biopsy, four had tumors identified as high-risk for aggressive metastasis, and five were identified as low-risk. When physicians know upfront which patient has a poor prognosis, they will monitor the person more closely to detect metastasis earlier and consider more aggressive treatments to increase their chance of survival, Young emphasized. Knowledge of metastatic risk will also help patients and their physicians decide whether to pursue clinical trials of experimental therapies that target metastasis.. Patients understand that no good treatment exists after their cancer spreads -- everyone wants to know what their metastasis risk is, she added. If the risk is low, its a giant relief and emotional burden off their shoulders. If the risk is high, it enables them to plan arrangements for their family and finances, and make the most of their remaining time alive. Pioneered by UCLA ophthalmic pathologist Dr. Ben Glasgow, the technique of ...
Results Three new genes from the colorectal cancer (CRC) metastasis signature, BOP1, CKS2 and NFIL3, were identified as direct transcription targets of β-catenin/TCF4. Overexpression and knocking down of these genes in CRC cells promoted and inhibited, respectively, experimental metastasis in mice, EMT and cell motility in culture. Cell migration was repressed by interfering with distinct signalling systems through inhibitors of PI3K, JNK, p38 mitogen-activated protein kinase and/or mTOR. Gene expression profiling identified a series of migration-promoting genes, which were induced by BOP1, CKS2 and NFIL3, and could be repressed by inhibitors that are specific to these pathways. ...
The invasive phenotype of breast tumors, determined by characteristics such as tumor cell motility and membrane perturbations, is clearly linked to cytoskeletal function. For example, recent studies have shown that certain metastasis-specific molecules (e.g., CD44v3,8-10 isoform [Bourguignon et al. 1998b, Bourguignon et al. 1999] and its associated matrix metalloproteinase, MMP-9 [Bourguignon et al., 1998b; Yu and Stamenkovic 1999], as well as Rho kinase [Bourguignon et al. 1999]) are closely associated with the cytoskeleton during tumor cell function. To further examine the regulatory mechanism(s) involved in cytoskeleton-mediated oncogenic signaling leading to tumor cell invasion and migration, we have focused on GEFs (the Dbl or DH family), such as Tiam1, which are known to display oncogenic capability and function as upstream activators of Rho-like GTPases (e.g., Rac1 or Cdc42; Woods et al., 1991; Habets et al. 1994; Michiels et al. 1995; Nobes and Hall 1995; Van Leeuwen et al. 1995). In ...
Since survival is limited, patients with cerebral metastasis NSCLC are not generally considered candidates for systemic therapy and are often excluded from clinical trials of systemic therapy. In recent years, there has been a shift towards a more aggressive local management in selected patients with solitary or oligo-metastatic metastases of the brain from NSCLC. Approach approaches include surgical resection and advanced radiation techniques such as Radiochirurgia stereotactic. In addition, patients with treated cerebral metastases who have good performance status have been included in many systemic therapy studies. A retrospective review of patients with stable cerebral metastases from NSCLC included in the chemotherapy study reported survival similar to patients with the advanced disease without cerebral metastases. However, all these observations may be subject to a biased selection ...
Occasionally, a bone metastasis of a GCCL could potentially be mistaken for a primary giant-cell tumor of bone - interestingly ... Spivach A, Borea B, Bertoli G, Daris G (July 1976). "[Primary lung neoplasm of rare incidence: giant cell carcinoma]". Minerva ... Within the small bowel, the jejunum seems to be a preferred site for metastasis of GCCL. GCCL also often metastasizes to bone, ... Hagihara N, Abe T, Wakamiya T, Sugita Y, Watanabe M, Tabuchi K (2010). "A case of brain metastasis from pulmonary giant cell ...
Metastasis to one or both adrenal glands is the most common form of malignant adrenal lesion, and the second most common ... An adrenal tumor or adrenal mass is any benign or malignant neoplasms of the adrenal gland, several of which are notable for ... Pheochromocytoma is a neoplasm composed of cells similar to the chromaffin cells of the mature adrenal medulla. ... List of included entries and references is found on main image page in Commons: File:Metastasis sites for common cancers.svg ...
The most common malignant neoplasms (cancers) of the liver are metastases; those arising from colorectal cancer are among the ... Most hepatectomies are performed for the treatment of hepatic neoplasms, both benign or malignant. Benign neoplasms include ... Prior to surgery, cytotoxic agents such as oxaliplatin given systemically for colorectal metastasis, or chemoembolization for ... repeat resections for reincident colorectal cancer metastases).[citation needed] Liver surgery is safe when performed by ...
breast cancer metastasis neoplasm chemotherapy Mouse models of breast cancer metastasis Phyllodes tumour John's Hopkins. " ... Brain metastases. Brain metastases occur in up to 10-15% of breast-cancer patients, and often (but not always) occur late in ... Bone metastases. The bones are a very common site of metastatic disease from breast cancer, and bone metastases can cause ... In breast cancer, spinal-cord compression occurs when a bone metastasis or spinal metastasis begins to push on the spinal cord ...
... of people already have metastases. Small-cell carcinoma is an undifferentiated neoplasm composed of primitive-appearing cells. ... pain from liver or bone metastases, or for treatment of brain metastases, which, in small-cell lung carcinoma, typically have a ... Of note, temozolomide yielded a response rate of 38% for brain metastases due to SCLC. In a clinical trial of 50 patients, ... Erasmus CE, Verhagen WI, Wauters CA, van Lindert EJ (November 2002). "Brain metastasis from prostate small-cell carcinoma: not ...
In its malignant form, metastasis to the lungs, liver, brain, and extremities may occur. It most commonly manifests itself in ... Hemangiopericytoma is a rare vascular neoplasm, or abnormal growth, that may either be benign or malignant. ...
Of further relevance is that this tumour is more commonly calcified than any other kidney neoplasm. Surgery is curative and no ... There is so far no evidence of metastases or local recurrence. Metanephric adenoma is diagnosed histologically. The tumours can ... the frequent gain of chromosomes 7 and 17 and losses of the Y chromosome that are typical of papillary renal cell neoplasms, ...
"A case of ovarian metastasis of gallbladder carcinoma simulating primary ovarian neoplasm: diagnostic pitfalls and review of ...
Metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes. N3. Any of:. Metastasis to scalene or supraclavicular ... Horn, L; Lovly, CM; Johnson, DH (2015). "Chapter 107: Neoplasms of the lung". In Kasper, DL; Hauser, SL; Jameson, JL; Fauci, AS ... Metastasis[edit]. Typical Napsin-A and TTF-1 immunostaining in primary lung carcinoma[1]. Histological type. Napsin-A. TTF-1. ... It may be useful in the treatment of bone metastases.[132]. Bronchoscopy[edit]. Several treatments can be administered via ...
1. 3. 2001). „Atypical pulmonary metastases: spectrum of radiologic findings". Radiographics. 21 (2): 403-417. PMID 11259704.. ... Tan D, Zander DS (2008). „Immunohistochemistry for Assessment of Pulmonary and Pleural Neoplasms: A Review and Update". Int J ...
There are four main groups of vaginal neoplasms: benign neoplasms, in situ neoplasms, malignant neoplasms, and neoplasms of ... "NCI Dictionary of Cancer Terms - Metastasis". National Cancer Institute. Retrieved 2018-03-13.. ... p. Neoplasm. ISBN 0781733901.. *^ "NCI Dictionary of Cancer Terms - Neoplasm". National Cancer Institute. Retrieved 2018-03-13. ... Vaginal tumors are neoplasms (tumors) found in the vagina. They can be benign or malignant.[1][a] A neoplasm is an abnormal ...
... parotid gland neoplasms or metastases. Sometimes, the facial nerve cannot be preserved during resection of these tumours. ...
... neoplasms are somewhat difficult to differentiate between being benign or malignant. Since the size and growth ... On few occasions, patients with Hürthle cell carcinoma have distant metastases in the lungs or surrounding bones. ... Some scientists have identified these mutations as deletions in the mitochondrial DNA of Hürthle cells found in neoplasms and ... Erickson, Lori A. "Hurthle Cell Thyroid Neoplasms." Atlas of Endocrine Pathology. Springer New York, 2014. 63-66. Hürthle, Karl ...
... which may be benign neoplasms) or else a malignant neoplasm (cancer). These neoplasms are also indicated, in the diagram below ... tissue invasion and metastasis.. Genetic instability is defined as an "enabling characteristic" that facilitates the ... The Hallmarks of Cancer as evolutionary adaptations in a neoplasm[edit]. In their landmark paper, The Hallmarks of Cancer,[3] ... Cells in neoplasms compete for resources, such as oxygen and glucose, as well as space. Thus, a cell that acquires a mutation ...
... more commonly a metastasis; or very rarely a primary neoplasm. The most common type is a sarcoma followed by lymphoma, ... Retroperitoneal fibrosis Retroperitoneal lymph node dissection It is also possible to have a neoplasm in this area, ...
... or metastases of other tumours. Often, since facial neoplasms have such an intimate relationship with the facial nerve, ... While this will inevitably lead to heightened paralysis, safe removal of a malignant neoplasm is worth the often treatable ... Common culprits are facial neuromas, congenital cholesteatomas, hemangiomas, acoustic neuromas, parotid gland neoplasms, ...
Malignant neoplasms are commonly called cancer. They invade and destroy the surrounding tissue, may form metastases and, if ... ICD-10 classifies neoplasms into four main groups: benign neoplasms, in situ neoplasms, malignant neoplasms, and neoplasms of ... The term 'neoplasm' is a synonym of "tumor". 'Neoplasia' denotes the process of the formation of neoplasms/tumors, the process ... "II Neoplasms". World Health Organization. Retrieved 19 June 2014.. *^ a b Abrams, Gerald. "Neoplasia I". Retrieved 23 January ...
A pattern of multiple small nodular metastases has been described as miliary carcinosis which has a radiographic appearance ... Young, Robert H. (2004). "Pseudomyxoma peritonei and selected other aspects of the spread of appendiceal neoplasms". Seminars ... Currall, Verity A.; Dixon, John H. (2008). "Synovial Metastasis". The Journal of Arthroplasty. 23 (4): 631-636. doi:10.1016/j. ... Carcinosis, or carcinomatosis, is disseminated cancer, forms of metastasis, whether used generally or in specific patterns of ...
Singh H, Nugent Z, Mahmud SM, Demers AA, Bernstein CN (March 2010). "Surgical resection of hepatic metastases from colorectal ... and left-sided colorectal neoplasms after colonoscopy: population-based study". J Natl Cancer Inst. 102 (2): 89-95. doi:10.1093 ...
... neoplasms is limited to lesions with no risk of nodal metastasis. Either polypectomy or endoscopic mucosal resection (EMR) is ... The resected size and shape can be controlled, en bloc resection is possible even in a large neoplasm, and neoplasms with ... So this technique can be applied to the resection of complex neoplasms such as large neoplasms, ulcerative non-lifting ... especially for large or ulcerative neoplasms. Recently, the ESD technique is applied to esophageal or colorectal neoplasms in ...
Calcifications are commonly present, as may be seen with slow-growing neoplasms. Although ASPS displays a relatively indolent ... course, the ultimate prognosis is poor and is often characterized by late metastases. ASPS is an extremely rare cancer. While ...
Chapter 107: Neoplasms of the lung. (编) Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J. Harrison's Principles ... Atypical pulmonary metastases: spectrum of radiologic findings. Radiographics. 2001-03-01, 21 (2): 403-17. PMID 11259704. doi: ... D'Antonio C, Passaro A, Gori B, Del Signore E, Migliorino MR, Ricciardi S, Fulvi A, de Marinis F. Bone and brain metastasis in ... Immunohistochemistry for Assessment of Pulmonary and Pleural Neoplasms: A Review and Update. Int J Clin Exp Pathol. 2008, 1 (1 ...
Tumors that express keratin include carcinomas, thymomas, sarcomas and trophoblastic neoplasms. Furthermore, the precise ... while metastases of colorectal carcinomas express K20, but not K7. Keratin is highly resistant to digestive acids if ingested, ... expression-pattern of keratin subtypes allows prediction of the origin of the primary tumor when assessing metastases. For ...
"Atypical pulmonary metastases: spectrum of radiologic findings". Radiographics 21 (2): 403-417. PMID 11259704. Cite uses ... "Immunohistochemistry for Assessment of Pulmonary and Pleural Neoplasms: A Review and Update". Int J Clin Exp Pathol 1 (1): 19- ...
... is a malignant form of a cystadenoma and is a malignant neoplasm derived from glandular epithelium, in which ... The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. ... It usually presents with omental metastases which cause ascites. Papillary serous cystadenocarcinoma "Female Genital Pathology ...
Finally, c-myc gene expression is relatively high in neoplasms, and it is often linked to poor prognosis. Bilateral ... Metastasis is most commonly to the liver and lung. Hormonal syndromes should be confirmed with laboratory testing. Laboratory ...
... parotid gland neoplasms, or metastases of other tumors. Other causes like viral, bacterial or fungal infections like chicken ...
... of cases have had local recurrence whereas some demonstrate regional lymph node or osseous metastasis. The rare neoplasms ... MCS is reported to have a high and continual risk of recurrence of metastasis, some patients experiencing metastasis nearly ... rate of metastasis and mortality in the order of 25%" (Ka, Gnangnon, and Diouf, 2016) with the highest recordings of metastases ... nodal metastasis, and distant metastasis, [respectively]" (Watarai, Amoh, Aki, Takasu, Katsuoka, 2011). In terms of prognosis ...
Intracranial neoplasm, brain tumour. Brain metastasis in the right cerebral hemisphere from lung cancer, shown on magnetic ... Secondary, or metastatic, brain tumors are more common than primary brain tumors,[2] with about half of metastases coming from ... Neoplasms will often show as differently colored masses (also referred to as processes) in CT or MRI results. ... The skull bone structure can also be subject to a neoplasm that by its very nature reduces the volume of the intracranial ...
Bone metastasis. *Bone tumor. C. *The Cancer Council Australia. *Cancer of unknown primary origin ... Salivary gland neoplasm. *Sarcoma. *Skin cancer. *Small intestine cancer. *Small-cell carcinoma ...
... metastasis - MHC - microbes - microbicide - Microsporidiosis - mitochondria - mitochondrial toxicity - molecule - molluscum ... neoplasm - nephrotoxic - neuralgia - neurological complications of AIDS - neuropathy - neutralization - neutralizing antibody ...
Low back pain may occur after metastasis to the retroperitoneum.[4] Some cases of seminoma can present as a primary tumour ... It is a malignant neoplasm and is one of the most treatable and curable cancers, with a survival rate above 95% if discovered ... Abdominal CT or MRI scans as well as chest imaging are done to detect for metastasis. The analysis of tumor markers also helps ... Stage 3 seminoma is characterized by the presence of metastasis outside the retroperitoneum-the lungs in "good risk" cases or ...
Isotopes commonly used in the treatment of bone metastasis are radium-223,[73] strontium-89 and samarium (153Sm) lexidronam.[74 ... Hypopituitarism commonly develops after radiation therapy for sellar and parasellar neoplasms, extrasellar brain tumours, head ... Many low-dose palliative treatments (for example, radiation therapy to bony metastases) cause minimal or no side effects, ... A major use of systemic radioisotope therapy is in the treatment of bone metastasis from cancer. The radioisotopes travel ...
"ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms ... "Islet Cell Tumors of the Pancreas / Endocrine Neoplasms of the Pancreas". The Sol Goldman Pancreas Cancer Research Center. ... In cases with localized disease and small cancers (,2 cm) with no lymph node metastases and no extension beyond the capsule of ... Farrell JJ, Fernández-del Castillo C (juni 2013). "Pancreatic cystic neoplasms: management and unanswered questions". ...
"Choroidal Metastasis - The Eye Cancer Network". Retrieved 2010-03-10.. *^ "Choroidal Nevus - The Eye Cancer Network". Retrieved ... Eye neoplasms can affect all parts of the eye, and can be a benign tumor or a malignant tumor (cancer). Eye cancers can be ... Retrieved from "" ...
... and palliative radiation therapy to known metastases. Spinal cord compression can occur with metastases to the spine and can be ... "Male Genitals - Prostate Neoplasms". Pathology study images. University of Virginia School of Medicine. Archived from the ... The route of metastasis to bone is thought to be venous as the prostatic venous plexus draining the prostate connects with the ... Bone scans should reveal osteoblastic appearance due to increased bone density in the areas of bone metastasis-opposite to what ...
Brain metastasis in the right cerebral hemisphere from lung cancer shown on T1-weighted magnetic resonance imaging with ... "CNS and Miscellaneous Intracranial and Instraspinal Neoplasms" (PDF). SEER Pediatric Monograph. National Cancer Institute. pp ... ವ್ಹೋಲ್ ಬ್ರೇನ್ ರಡಿಯೇಶನ್ increases risk of learning and memory problems in cancer patients with brain metastases ...
Other sites / metastases[edit]. Metastasis of carcinoid can lead to carcinoid syndrome. This is due to the over-production of ... cystic neoplasms: Serous microcystic adenoma. *Intraductal papillary mucinous neoplasm. *Mucinous cystic neoplasm ... In some cases, metastasis may occur. Carcinoid tumors of the midgut (jejunum, ileum, appendix, and cecum) are associated with ... for arresting the growth of the tumors and prolonging survival in patients with liver metastases, though these are currently ...
Cytoplasmic p21 expression can be significantly correlated with lymph node metastasis, distant metastases, advanced TNM stage ( ... Neoplasm: Tumor suppressor genes/proteins and Oncogenes/Proto-oncogenes. Ligand. Growth factors. ... Metastatic canine mammary tumors display increased levels of p21 in the primary tumors but also in their metastases, despite ... a classification of cancer staging that stands for: tumor size, describing nearby lymph nodes, and distant metastasis), depth ...
腦垂腺(英语:Pituitary neoplasm). *垂體腺瘤(英语:Pituitary adenoma):泌乳素瘤(英语:Prolactinoma) ... 附註:並非所有腦腫瘤都發生在神經組織;另外,並非所有神經組織腫瘤都在腦部(參見轉移性腦癌(英
Note: Not all brain tumors are of nervous tissue, and not all nervous tissue tumors are in the brain (see brain metastasis).. ... Nervous tissue tumors/NS neoplasm/Neuroectodermal tumor (ICD-O 9350-9589) (C70-C72, D32-D33, 191-192/225) ...
Large cell lung carcinoma (LCLC) is a heterogeneous group of undifferentiated malignant neoplasms originating from transformed ... or patients with distant metastasis outside of the thoracic cavity. ... in that the tumor cells lack light microscopic characteristics that would classify the neoplasm as a small-cell carcinoma, ...
Neoplasm CD34[1] Stromelysin-3[10] Factor XIIIa[6] Dermatofibroma - + + Dermatofibrosarcoma protuberans + - - ...
Secondary neoplasm[edit]. Development of secondary neoplasia after successful chemotherapy or radiotherapy treatment can occur ... Cancer is the uncontrolled growth of cells coupled with malignant behaviour: invasion and metastasis (among other features).[ ... Hendriks JM, Van Schil PE (1998). "Isolated lung perfusion for the treatment of pulmonary metastases". Surgical Oncology. 7 (1- ... The most common secondary neoplasm is secondary acute myeloid leukemia, which develops primarily after treatment with ...
Note: Not all brain tumors are of nervous tissue, and not all nervous tissue tumors are in the brain (see brain metastasis).. ... Nervous tissue tumors/NS neoplasm/Neuroectodermal tumor (ICD-O 9350-9589) (C70-C72, D32-D33, 191-192/225) ...
... studies in a logical fashion to obtain information about the size of the neoplasm and the extent of its invasion and metastasis ... 8560-8580) Complex epithelial neoplasms. Carcinoma In situ[edit]. The term carcinoma in situ (or CIS) is a term for cells that ... distant metastasis).[10]. If this process of continuous growth, local invasion, and regional and distant metastasis is not ... a process called metastasis. If unchecked, tumor growth and metastasis eventually creates a tumor burden so great that the host ...
Metastasis. Main article: Metastasis. Metastasis is the spread of cancer to other locations in the body. The dispersed tumors ... They form a subset of neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often ... Metastasis. Main article: Metastasis. Cancer can spread from its original site by local spread, lymphatic spread to regional ... Metastasis is common in the late stages of cancer and it can occur via the blood or the lymphatic system or both. The typical ...
Intracranial neoplasm, brain tumour. Brain metastasis in the right cerebral hemisphere from lung cancer, shown on magnetic ... The skull bone structure can also be subject to a neoplasm that by its very nature reduces the volume of the intracranial ... "CNS and Miscellaneous Intracranial and Intraspinal Neoplasms" (PDF). SEER Pediatric Monograph. National Cancer Institute. pp. ... More generally a neoplasm may cause release of metabolic end products (e.g., free radicals, altered electrolytes, ...
Cadherin-1 in metastasis[edit]. Transitions between epithelial and mesenchymal states play important roles in embryonic ... Neoplasm: Tumor suppressor genes/proteins and Oncogenes/Proto-oncogenes. Ligand. Growth factors. ... Loss of E-cadherin function or expression has been implicated in cancer progression and metastasis.[10][11] E-cadherin ... Beavon IR (August 2000). "The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation". European ...
en:Neoplasm (40) → 신생물 *en:Nephrotic syndrome (38) → 신증후군 *en:Nervous system disease (4) ... en:Bone metastasis (6). *en:Botulism (61) → 보툴리누스 중독 *en:Brain damage (23) → 뇌손상 ...
Brain metastasis in the right cerebral hemisphere from lung cancer shown on T1-weighted magnetic resonance imaging with ... Gurney, James G; Smith, Malcolm A; Bunin, Greta R. "CNS and Miscellaneous Intracranial and Instraspinal Neoplasms" (PDF). SEER ... Whole Brain Radiation increases risk of learning and memory problems in cancer patients with brain metastases ...
Coley, William (1949). Neoplasms of Bone. New York: Medical Book Department of Harper & Brothers. pp. 565-570.. ... Bessie died just ten weeks later due to widespread metastasis of the original cancer. Bessie's death had a profound effect on ... may sometimes play a significant role in preventing or retarding malignant recurrence or metastases." [18] ...
Sung Bin Park, MD, Hak Hee Kim, MD, [...], ja Gyungyub Gong, MD, Thymic Metastasis in Breast Cancer: A Case Report, Korean J ... Tseng-Tong Kuo, Classification of thymic epithelial neoplasms: a controversial issue coming to an end?, J.Cell.Mol.Med. 5. ... Fujita A, Nakazato Y, Tachibana K, Goya T., Thymic metastasis of laryngeal cancer. Kyobu Geka. september 2011;64(10):912-5., ... Pierre Demondiona, Pierre Validireb, Jean Trédanielc ja Dominique Gossota, Thymic metastasis from lung carcinoma, Interact ...
... in cancers is characterized by anaplasia, invasiveness, and metastasis.[1] Malignant tumors are also characterized ... Malignancy, malignant neoplasm and malignant tumor are synonymous with cancer. *Malignant ascites ...
Lung cancer is an extremely heterogeneous family of malignant neoplasms,[1] with well over 50 different histological variants ... and metastasis characteristic of malignant tumors. The increased differential activity usually results in fewer troubling side ...
Imaging studies can show metastasis in testicular cancer (TCa); however, a test for risk of metastasis in TCa has not been ... The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate ... Amino-terminal enhancer of split gene AES encodes a tumor and metastasis suppressor of prostate cancer. Major cause of cancer ... Impact of subsequent metastases on costs and medical resource use for prostate cancer patients initially diagnosed with ...
... develop hepatic metastases in 50-95 %. The aims of this study were to evaluate the outcome/prognosis of patients following ... Patients with neuroendocrine neoplasms (NEN) develop hepatic metastases in 50-95 %. The aims of this study were to evaluate the ... Surgical therapy of neuroendocrine neoplasm with hepatic metastasis: patient selection and prognosis. ... ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms ...
Neoplasms Metastasis Terminated Phase 2 Trials for Paclitaxel (DB01229). Back to Neoplasms Metastasis ...
Neoplasms Metastasis Completed Phase 3 Trials for Actinium (DB12860). Back to Neoplasms Metastasis ...
Tumor-to-tumor metastasis in thyroid neoplasms is exceedingly uncommon [14, 15]. In the present case, the identification of ... develop metachronous metastases [2]. In autopsy series, thyroid metastases from CCRCC have been detected in 4-5% of patients, ... were the most common sites of metastases origin in autopsy series [9-12]. While in autopsy series, metastases to the thyroid ... Metastases from nonthyroid malignancies to the thyroid gland have been reported in 1.4%-3% of all patients who have surgery for ...
Distant metastasis of gastrointestinal endocrine neoplasm is definitely resistant to available. January 20, 2019. ... Distant metastasis of gastrointestinal endocrine neoplasm is definitely resistant to available remedies. G. , Kuang W. J. , ... Asano M. , Yukita A. , Matsumoto T. , Kondo S. and Suzuki H.Inhibition of tumor growth and metastasis by an immunoneutralizing ... and experimental metastasis . Cancer Res. , 56 , 172 C 181 ( 1996. ). [PubMed] 29. ) Dvorak H. F. , Brown L. F. , Detmar M. and ...
The patient was admitted to our Department in 2017 with a liver metastasis of a neuroendocrine tumour. On admission she had no ... Liver metastasis of a neuroendocrine neoplasm of unknown primary origin in a female patient with a history of breast cancer. ... "Liver metastasis of a neuroendocrine neoplasm of unknown primary origin in a female patient with a history of breast cancer". ... "Liver metastasis of a neuroendocrine neoplasm of unknown primary origin in a female patient with a history of breast cancer." ...
... ... Introduction: Up to 73% of patients with neuroendocrine neoplasms (NEN) present with distant metastases at diagnosis. Advanced ... in patients with bone metastases (BM). In neuroendocrine neoplasms (NEN), BM are a negative prognostic factor, however tend to ... in Patients with Bone Metastases of Neuroendocrine Neoplasms. Introduction: Antiresorptive therapy (ART) with bisphosphonates ...
Expression of Oncofetal Protein IMP3 in Lymph Node Metastases of Small Intestine Neuroendocrine Neoplasms: A New Predictor of ... Introduction: Small intestine neuroendocrine neoplasm (SINENs) are heterogeneous neoplasms arising from endocrine cells of the ... Introduction: Neuroendocrine neoplasms of unknown primary (NENs-UP) account for 10-13% of all NENs and show different biologic ... 1069 Gastric Neuroendocrine Neoplasms and Long-Term Proton Pump Inhibitors: Need for a Revision of Classifications?. ...
However, symptomatic brain metastases are associated with dismal prognosis, so early detection and treatment could be advisable ... Overall, the risk for symptomatic brain metastases is low in GEP-NEN and bronchopulmonary NEN patients. Age above 60 and poor ... Overall, the median period from first diagnosis of the tumor disease up to diagnosis of brain metastasis was 5.0 months. ... The median overall survival (mOS) and mOS after diagnosis of brain metastases (BM) were calculated using Kaplan-Meier analysis ...
Cervical lymph node metastases in epithelial neoplasms of the upper respiratory-digestive tract]. by Chiara Cavina et al. ... Cervical lymph node metastases in epithelial neoplasms of the upper respiratory-digestive tract].. *. Chiara Cavina, G Pelú ... article{Cavina1962CervicalLN, title={[Cervical lymph node metastases in epithelial neoplasms of the upper respiratory-digestive ...
"Neoplasm Metastasis" by people in this website by year, and whether "Neoplasm Metastasis" was a major or minor topic of these ... "Neoplasm Metastasis" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... Below are the most recent publications written about "Neoplasm Metastasis" by people in Profiles. ... Below are MeSH descriptors whose meaning is more general than "Neoplasm Metastasis". ...
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. ...
Silencing of a novel tumor metastasis suppressor gene LASS2/TMSG1 promotes invasion of prostate cancer cell in vitro through ... Preliminary studies showed that it not only suppressed tumor growth but also closely related to tumor metastasis, however, its ... Homo sapiens longevity assurance homologue 2 of yeast LAG1 (LASS2), also known as tumor metastasis suppressor gene 1 (TMSG1), ... In primary cancer cultures and cell lines, their antitumor actions were by inhibiting cancer proliferation, metastasis, and ...
Tag: Neoplasm metastasis. Outcomes Following Complete Surgical Metastasectomy for Patients with Metastatic Renal Cell Carcinoma ...
Based on autopsy reports, lung metastases occur in 33% to 50% of all non-lung malignancies. Most metastases are caused by the ... Beware: there are other diseases that can mimic lung neoplasms:*How and/or why did the patient develop a lung neoplasm?*Which ... Results of resection of other solitary metastases or multiple metastases vary greatly, depending on the biology of the primary ... What other considerations exist for patients with lung neoplasms?. There are no genetic predispositions to the neoplasms ...
Potential symptoms of plasma cell neoplasms include fatigue, bone pain, weakness and fevers, says the National Cancer Institute ... What Symptoms Occur With Bone Metastasis?. A: Symptoms of bone metastasis include bone pain, leg weakness, broken bones and ... A plasma cell neoplasm is a disease that causes the human body to produce too many plasma cells, reports the National Cancer ... Plasma cell neoplasms are more common in middle-aged people and senior citizens, with males more at risk than females, notes ...
no metastasis Accumulation of cancer cells The expanding mass compresses nearby blood vessels leading to necrosis. increasing ... Distant metastasis Irritation and build up of fluid in adjacent tissues T.Unblocked blood vessels drain towards the venous ... and area of inflammation around the metastasis Cancer moves to etracellular matrix by secreting enzymes Surrounding ... Chemotherapy Poor Prognosis Organ Failure New metastasis on lungs and other organs Lymphadema Cardiac Arrest Failure of liver ...
Malignant neoplasms have the ability to invade adjacent structures, spread through the lymphatic system or metastasize to ... Molecular Basis of Malignant Neoplasms Metastasis. The main difference between benign and malignant neoplasms lies in the ... Organ-specific Metastasis in Malignant Neoplasms. The most commonly involved organs in metastatic disease are the lungs, liver ... Angiogenesis and Lymphangiogenesis in Malignant Neoplasms. At this stage, it should be evident that malignant neoplasms in ...
Metastasis research protocols edited by Miriam Dwek, Susan A. Brooks, Udo Schumacher.2nd ed.. *. Access via Springer for Pitt ... Metastasis research protocols. edited by Miriam Dwek, Udo Schumacher, Susan A. Brooks.2nd ed.. *. Access via Springer for Pitt ... Metastasis research protocols edited by Susan A. Brooks and Udo Schumacher.. *. Access via Springer for Pitt and UPMC users ... Metastasis research protocols. edited by Susan A. Brooks and Udo Schumacher.. *. Access via Springer for Pitt and UPMC users ...
... metastases are tumors caused by cancer cells that break off from the primary tumor and attach to the bones, the American Cancer ... What symptoms are associated with a neoplasm?. * Q: Where can you find lymphoma images?. ... What is the life expectancy with bone metastases?. A: The life expectancy for a person with bone metastases depends on many ... Osseous, or bone, metastases are tumors caused by cancer cells that break off from the primary tumor and attach to the bones, ...
Metastasis. Material type: Book; Format: print Publisher: Chichester : Wiley, 1988Availability: Items available for loan: WHO ...
Brain Neoplasms - psychology - popular works Neoplasm Metastasis - diagnosis Neoplasm Metastasis - therapy Language. English ... Brain Neoplasms - secondary Brain Neoplasms - therapy Brain Neoplasms - radiotherapy Neoplasm Metastasis - therapy Radiosurgery ... Neoplasm Metastasis - physiopathology Neoplasm Metastasis - therapy ISBN. 9780521887212 Language. English Material Type. Book ... Lung Neoplasms - drug therapy Lung Neoplasms - therapy Neoplasm Metastasis - therapy ISBN. 9781891483585 Language. English ...
What is Secondary malignant neoplasm? Meaning of Secondary malignant neoplasm as a legal term. What does Secondary malignant ... Definition of Secondary malignant neoplasm in the Legal Dictionary - by Free online English dictionary and encyclopedia. ... metastasis. (redirected from Secondary malignant neoplasm). Also found in: Dictionary, Thesaurus, Medical, Encyclopedia. ... a href=,metastasis,/a,. *Facebook ...
Metastases of malignant neoplasms: Historical, biological, & clinical considerations. Review article. In Press, Corrected Proof ... Diagnosis and management of metastatic neoplasms with unknown primary. Review article. In Press, Corrected Proof, Available ...
... metastasis or primary neoplasm? by Silvia Bondini et al. ... metastasis or primary neoplasm?}, author={Silvia Bondini and ... Squamous cell carcinoma of the liver: metastasis or primary neoplasm?. *. Silvia Bondini. , Simona Leoni. , Luigi Bolondi ...
Neoplasm Metastasis - psychology - videocassettes Survivors - videocassettes Breast Neoplasms - psychology - videocassettes ...
NAP1L1 is over-expressed in pancreatic neuroendocrine neoplasm metastases and epigenetically promotes cell proliferation ... 38 primaries and 5 metastasis), NAP1L1 was over-expressed in metastasis (p , 0.001), expression which was inversely correlated ... in the pancreatic neuroendocrine neoplasm cell line BON in vitro (p , 0.0001) and resulted in significantly smaller (p , 0.05) ... which is upregulated in small intestinal neuroendocrine neoplasms (NENs), has been implicated in cell cycle progression. As ...
The ovarian metastases from gallbladder mimics primary neoplasm isnt seen before and mentioned in English literatures before. ... The non-specific symptoms make the challenge to difference the primary malignant neoplasm. The rarely diagnosis must take in ... From: Ovarian metastases from gallbladder mimics primary ovarian neoplasm in young patient: a case report ...
  • 2903 Bone Metastases (BM) in Neuroendocrine Tumors (NET): Imaging Characteristics and Clinical Implications. (
  • In all cases IMP3 expression was evaluated on primary tumors and, when available, on nodal and distant metastases.The medical records and pathological slides were used to determine clinical characteristics, pathological diagnoses, and outcome information. (
  • Both multiple endocrine neoplasia type 1 (MEN1)-related-gastrinomas and Gastrointestinal Stromal Tumors (GISTs) are rare neoplasms, and their association has been rarely reported. (
  • Brain metastases (BM) are rarely reported in patients with neuroendocrine carcinoma (NEC) of non-lung origin and neuroendocrine tumors (NET) of the gastroenteropancreatic (GEP) or bronchopulmonary system. (
  • Other primary malignancies with a tendency for pulmonary metastases include melanoma, sarcomas, and thyroid and germ cell tumors. (
  • Flushing and diarrhea (carcinoid syndrome) resulting from excessive serotonin production has been reported with bronchial carcinoid tumors, but these patients usually have significant hepatic metastases, and the pulmonary tumor is usually greater than 5 cm. (
  • Hypertrophic pulmonary osteoarthropathy as well as digital clubbing may occur with solitary fibrous tumors in up to 20% of cases, but it is otherwise uncommon with pulmonary metastases. (
  • Osseous, or bone, metastases are tumors caused by cancer cells that break off from the primary tumor and attach to the bones, the American Cancer Society explains. (
  • Usually, there have already been metastases at other sites, or the tumors are detected at various sites synchronously ( 2 , 3 ). (
  • Metastasis from the contralateral breast is a diagnostic consideration when there is bilateral involvement (or history thereof), the histologic appearances of the tumors in the breasts are similar, and there is no evidence of in situ carcinoma in the contralateral breast. (
  • Although it is common in the lung cancer literature to refer to histologically mixed tumors containing significant numbers of malignant giant cells as "giant-cell carcinomas", technically a diagnosis of "giant-cell carcinoma" should be limited strictly to neoplasms containing only malignant giant cells (i.e. "pure" giant-cell carcinoma). (
  • Bone metastases are common in the progression of various tumors such as prostate, breast, and lung carcinoma, and they often entail an occurrence of progressive pain. (
  • Calretinin is considered a specific and reliable marker for differentiation of sex cord-stromal tumors in humans, but its expression is demonstrated in all types of canine testicular neoplasms , including germ cells tumor (seminoma) and sex cord-stromal tumors (Sertoli cell and Leydig cell tumors). (
  • Up-regulation or down-regulation of tight junctions (TJ) has been reported in different forms of epithelial cancers, such as colorectal cancer , pancreatic cancer, and breast cancer and is believed to be responsible for cancer invasiveness and metastasis properties. (
  • While connexin loss of gap junctions has been reported to be a late finding in malignant neoplasms, desmosomes are believed to be impaired early in the disease process and are responsible for early invasiveness and metastasis . (
  • In CCRCC patients, a particularly prolonged survival rate may be achieved with the appropriate therapy, in contrast to the ominous prognosis typically found in patients with thyroid metastases from other origins. (
  • However, symptomatic brain metastases are associated with dismal prognosis, so early detection and treatment could be advisable. (
  • Results: Overall, for g-NENs without distant metastasis, the resected group had a better prognosis than the unresected group ( p =0.0019). (
  • Conclusions: Resection can significantly improve the prognosis of g-NENs patients without distant metastasis, and 2cm can be used as a resection threshold. (
  • The selection of relevant genes for breast cancer metastasis is critical for the treatment and prognosis of cancer patients. (
  • The pure-IMPC cases had higher incidences of lymphatic invasion and lymph node metastasis, and also showed a poorer prognosis. (
  • 223Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience. (
  • Radium-223 (223Ra) chloride, an alpha emitter, has been shown to improve overall survival (OS) and pain control, and to delay skeletal-related events, in patients with castration-resistant prostate cancer (CRPC) and bone metastases. (
  • Amino-terminal enhancer of split gene AES encodes a tumor and metastasis suppressor of prostate cancer. (
  • Major cause of cancer death is its metastasis to the vital organs. (
  • Association between perioperative glucocorticoids and cancer metastasis and survival in patients undergoing radical cystectomy for urothelial carcinoma of the bladder: A single-center retrospective study. (
  • Struk-Panfill M, Błaut K, Pęksa R, Kmieć P, Sworczak K. Liver metastasis of a neuroendocrine neoplasm of unknown primary origin in a female patient with a history of breast cancer. (
  • Due to unknown primary site of the metastasis and given the patient's history of breast cancer, it was suspected that the breast cancer was in fact a neuroendocrine tumour. (
  • Li N, Liu Y, Duan J, Yang B, Bai H, Sun R, Yu L, Wang J. Prognostic significance of molecular characteristics of cerebrospinal fluid for non-small cell lung cancer patients with leptomeningeal metastasis. (
  • While lung cancer is the most common cause of malignant lesions in the lungs, many other malignant and benign lung neoplasms may mimic primary lung cancer. (
  • Potential symptoms of plasma cell neoplasms include fatigue, bone pain, weakness and fevers, says the National Cancer Institute. (
  • A plasma cell neoplasm is a disease that causes the human body to produce too many plasma cells, reports the National Cancer Institute. (
  • no metastasis Accumulation of cancer cells The expanding mass compresses nearby blood vessels leading to necrosis. (
  • This metastatic phenomenon is responsible for most of the cancer-related mortality and a deeper understanding of its mechanisms can help in developing more specific treatments for malignant neoplasms. (
  • Objectives: To compare histopathological and clinical findings of metastasis to the temporal bone with previous reports and to determine the prevalence of these metastases in patients with nonsystemic cancer. (
  • The study will use an Ommaya reservoir that drains into brain metastases to deliver activated, autolous dendritic cells to the tumor lesion, for patients who are 18 - 75 years old who have brain metastases from either lung cancer or breast cancer. (
  • Identification of Genes Involved in Breast Cancer Metastasis by Integrating Protein-Protein Interaction Information with Expression Data. (
  • This article proposes a new Random Forest (RF)-based algorithm to identify important variables highly related with breast cancer metastasis, which is based on the important scores of two variable selection algorithms, including the mean decrease Gini (MDG) criteria of Random Forest and the GeneRank algorithm with protein-protein interaction (PPI) information. (
  • Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy. (
  • Average Pain Score 5 at Screening for the index bone metastasis cancer pain site. (
  • Bone metastasis is cancer that starts in one area and then spreads to a bone. (
  • Your risk for bone metastasis is higher if you have had cancer for a long time. (
  • Purpose: To evaluate planning quality of SBRT with multiple lung metastases generated with Pinnacle and Tomotherapy Methods: Nine randomly selected patients diagnosed with non small-cell lung cancer with multiple lesions were planned with Pinnacle (version 9.2) and Tomotherapy (version 4.2). (
  • Fulvestrant (ICI 182 780, ICI) has been used in treating patients with hormone-sensitive breast cancer, yet initial or acquired resistance to endocrine therapies frequently arises and, in particular, cancer recurs as metastasis. (
  • Our results indicate that targeting the GPR30 signaling may be a potential strategy to reduce metastasis and improve the efficacy of antiestrogens in treatment of advanced breast cancer. (
  • To evaluate the influence of perinephric (PN) and renal sinus (RS) fat infiltration on cancer-specific survival beyond other prognostic factors, as the Tumour-Node-Metastasis (TNM) classification system defines stage T3a renal cell carcinoma (RCC) as infiltration of perirenal fat and/or direct infiltration of the adrenal gland. (
  • Nylen CO Cancer metastasis in the temporal bone simulating acute inflammation in the middle ear. (
  • 5Radiation Oncology, Kempten Clinic, Kempten, Germany Purpose: Leptomeningeal metastasis (LM) is an increasingly common complication of late-stage systemic cancer, for which there is no standard treatment. (
  • Main neoplasms included breast cancer, lung cancer, and lymphoma. (
  • Furthermore, malignant aggressiveness of lung cancer cells was detected after miR-133a upregulation by CCK-8, flow cytometry, and Transwell assays and in vivo tumorigenesis and metastasis experiments. (
  • miR-133a restoration curtailed growth and metastasis of lung cancer cells in vitro and in vivo. (
  • Bile ducts are not among the common sites of metastasis from breast cancer. (
  • Few cases of obstructive jaundice due to metastatic breast cancer have been described in the literature and they mostly resulted from widespread liver metastases that eventually involved the bile ducts. (
  • Sporadic reports have been published about the involvement of the ampulla by breast cancer metastasis. (
  • 4-6 Breast cancer metastases occur through contiguous, lymphatic and hematogenous spread. (
  • However, an additional 50% of patients who are originally diagnosed with locally advanced disease later develop metastases, commonly to the lung, resulting in significant mortality among patients with bladder cancer ( 1 , 2 ). (
  • We recently showed that the GDP dissociation inhibitor, RhoGDI2, is a metastasis suppressor in a bladder cancer lung metastasis model ( 4 ). (
  • The clinical importance of RhoGDI2 loss of function was validated by showing that reduced or absent RhoGDI2 expression is strongly correlated with the development of metastasis, resulting in decreased survival following therapy for locally advanced bladder cancer ( 5 ). (
  • A Genomic-clinicopathologic Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer. (
  • Eye neoplasms can affect all parts of the eye, and can be a benign tumor or a malignant tumor (cancer). (
  • The preoperative clinical workup of an apparently healthy patient with a breast mass can be cursory and is unlikely to exclude a metastasis from a clinically inapparent (that is, "occult") nonmammary malignant neoplasm (NMMN). (
  • Metastatic disease must be considered as a cause of hearing loss in patients with a history of malignant neoplasm. (
  • A malignant neoplasm (abnormal growth) located on the ovaries. (
  • In addition the ICD-10 code C78.7 Secondary malignant neoplasm of liver and intrahepatic bile duct and a code from category C18. (
  • Malignant neoplasm of colon would be recorded. (
  • Here, we present a case of recurrent CCRCC, with metastases to both the mediastinal lymph nodes and the thyroid gland 10 years after nephrectomy. (
  • Metastases have been described in the ipsilateral axillary lymph nodes in a substantial proportion of patients with metastases in the breast ( 2 ). (
  • In spite of three times of radiofrequency ablation, the burden of hepatic metastasis has increased continuously and multiple intra-abdominal lymph nodes metastases were detected, and ascites and peripheral edema occurred. (
  • 68Ga-DOTA-TATE PET/CT plays an important role in neuroendocrine neoplasm(NEN)diagnosis and biological charecteristcs evaluation.Skeleton is the second common metastatic organ in NEN after liver and it affects the quality of patient's life. (
  • Up to 73% of patients with neuroendocrine neoplasms (NEN) present with distant metastases at diagnosis. (
  • The median overall survival (mOS) and mOS after diagnosis of brain metastases (BM) were calculated using Kaplan-Meier analysis. (
  • Overall, the median period from first diagnosis of the tumor disease up to diagnosis of brain metastasis was 5.0 months. (
  • Nearly 20% of the patients with small cell lung carcinoma (SCLC) demonstrate brain metastases at initial diagnosis and about half of the patients develop brain metastases during follow up [ 2 ]. (
  • Thus, when faced with a mammary neoplasm that has unusual clinical, radiologic, or histologic features, it is important to consider metastasis in the differential diagnosis. (
  • The interval between initial diagnosis of a NMMN and mammary metastases is usually about 2 years-but it can vary from a few weeks to several years. (
  • From this group of dogs, 4 out of 5 neoplasms (80%) were diagnosed as complex carcinoma by histopathology diagnosis. (
  • At the time of diagnosis, a SPN was detected at only pancreas and there was no evidence of metastasis. (
  • In 10% of the cases distant metastases are already present at the time of the diagnosis. (
  • The patient was admitted to our Department in 2017 with a liver metastasis of a neuroendocrine tumour. (
  • Squamous cell carcinoma of the liver: metastasis or primary neoplasm? (
  • My liver metastasis was described as significant on inspection and around 90% of the tumours were removed during this procedure leaving around half a dozen sub-centimetre deposits. (
  • Here, we report three cases of metachronous liver metastasis after long-term follow-up of endoscopic mucosal resection (EMR) for rectal NEN. (
  • Here, we report three cases of metachronous liver metastasis after long-term follow-up of endoscopic mucosal resection (EMR) and discuss the current problems underlying the treatment options for small rectal NEN with a review of the literature. (
  • Since immunohistochemistry staining of the liver metastasis showed somatostatin-2 receptor (SSTR-2) positivity, monthly intramuscular octreotide 30 mg was administered. (
  • She died of liver metastasis 1 year after the initial treatment. (
  • Clear cell renal cell carcinoma (CCRCC) is the most common origin for metastasis in the thyroid. (
  • Clear cell renal cell carcinoma (CCRCC) is the most frequent histological type, and although the clinical course of CCRCC is unpredictable, there is a high probability of late distant metastasis occurring in unusual locations [ 1 - 3 ]. (
  • Radiologic techniques such as MRI (magnetic resonance imaging) and FDG-PET/CT (fluorodeoxyglucose-positron emission tomography-computed tomography) have also detected metastases in the breast from carcinoma of the thyroid ( 7 ), ovary ( 8 ), and soft tissue liposarcoma ( 9 ). (
  • The aim of this study is to evaluate the efficacy of 5- fluorouracil + Mitomycin for the patients with pulmonary metastasis of hepatocellular carcinoma who had progressive disease with sorafenib. (
  • Extrahepatic metastasis of hepatocellular carcinoma has recently been paradoxically increasing due to increased survival with effective locoregional therapies. (
  • We provide evidence suggesting that complex carcinoma is the most frequent mammary tumor in bitches in our city and it is highly related to lung metastasis. (
  • To test the hypothesis that the endothelin axis is important in lung metastasis, lung metastatic bladder carcinoma cells were injected in mice treated with the endothelin receptor-specific antagonist, atrasentan, thereby blocking engagement of the up-regulated ET-1 ligand with its cognate receptor. (
  • The main difference between benign and malignant neoplasms lies in the ability of malignant neoplasms to metastasize to distant organs or invade adjacent structures. (
  • However, because of benign feature of SPN and extremely rare incidence of recurrence and metastasis, there is no specific treatment guideline for metastatic SPN. (
  • A benign epithelial neoplasm characterised by the formation of finger-like projections from the epithelial surface. (
  • High incidence of benign testicular neoplasms diagnosed by ultrasound. (
  • Benign nodal lesions mimicking metastases from pediatric renal neoplasms. (
  • A review of cases entered on the NWTS has uncovered a number of cases where benign lymph node findings were mistaken for metastases. (
  • Fingerprint Dive into the research topics of 'Benign nodal lesions mimicking metastases from pediatric renal neoplasms. (
  • Plasma cell neoplasms are more common in middle-aged people and senior citizens, with males more at risk than females, notes the NCI. (
  • The patient was treated with sunitinib and finally died due to CCRCC distant metastases 6 years after the thyroidectomy. (
  • Objective To investigate the features and risk factors associated with lymph node metastasis in colorectal neuroendocrine neoplasm . (
  • Hepatectomy has been the standard treatment for metachronic metastases of non-colorectal (NCR) origin, mainly when the disease-free interval is more than two years. (
  • The authors report the case of a female patient with two metachronic metastases (ten years of disease-free survival), of non-colorectal origin (adenocarcinoma of small intestine), treated by laparoscopic left lateral segmentectomy (left hepatic lobectomy) with success. (
  • Hepatectomy has been selected as the curative treatment of choice for metastases of colorectal (CR) origin. (
  • This guidance replaces NICE interventional procedures guidance on selective internal radiation therapy for colorectal metastases in the liver (IPG93). (
  • Patients in whom an R1 ( n = 23) or R2 ( n = 33) resection of their hepatic metastasis could be achieved had a 10-year survival of 53.4 and 51.4 %, respectively. (
  • Hyams grading as a predictor of metastasis and overall survival in esthesioneuroblastoma: a meta-analysis. (
  • The incidence of bone metastases (BM) in patients with NENs is 12-25%, and skeletal related events (SREs) occur in up to 21% of affected cases. (
  • Transcatheter-Arterial embolization (TAE) is an established regional, palliative treatment option for liver metastases in patients (pts) with neuroendocrine neoplasms (NENs). (
  • Neuroendocrine neoplasms of unknown primary (NENs-UP) account for 10-13% of all NENs and show different biologic behavior, histologic appearance and clinical outcome. (
  • Gastroenteric neuroendocrine neoplasms (GE-NENs) display highly variable clinical behavior. (
  • Background: Resection is the main method for treating gastric neuroendocrine neoplasms (g-NENs). (
  • Methods: In this study, 929 g-NENs patients without distant metastasis were collected and analyzed (857 patients from the SEER database, 72 patients from Wuhan Union Hospital or the First Affiliated Hospital of Shihezi University). (
  • For g-NENs within the size of endoscopic resection, which localized in situ and T1, or with well-differentiated morphology, or w/wo lymph node metastasis without distant metastasis, endoscopic resection is feasible. (
  • We report results of using isolated hepatic perfusion (IHP) in patients with advanced progressive liver metastases (LM) from pancreatic and gastrointestinal neuroendocrine neoplasms (NENs). (
  • Rectal neuroendocrine neoplasms (NENs) are rare, but their incidence has increased in recent years. (
  • The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. (
  • Hematopoietic and lymphoid neoplasms involving the breast are sometimes listed under the rubric of breast "metastases," but they are best regarded as either primary breast neoplasms or as a manifestation of a systemic condition, depending upon the extent of organ involvement. (
  • Nonetheless, primary melanocytic lesions of the breast are exceedingly less common than metastatic melanocytic neoplasms. (
  • Methods: Autopsy records of 864 patients were screened to select those with primary nondisseminated malignant neoplasms. (
  • Clinical records and autopsy reports were reviewed for demographic data, clinical course, otologic and vestibular manifestations, site of primary and its histological features, extent of metastasis, and mode of spread. (
  • Results: Of 212 patients with primary nondisseminated malignant neoplasms, 47 had metastases to the temporal bone (76 temporal bones). (
  • Temporal bone metastases were not observed in cases where the primary tumor was adequately treated. (
  • Systemic treatment for the primary malignancy or bone metastasis started within 30 days of the Baseline Assessment Period. (
  • Primary testicular neoplasms are common in dogs greater than 6 years of age and with a mean age of 10 years (Bethany et al. (
  • A ureteral neoplasm is a type of tumor that can be primary, or associated with a metastasis from another site. (
  • Surveillance of Low-Grade Appendiceal Mucinous Neoplasms With Peritoneal Metastases After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Are 5 Years Enough? (
  • Fingerprint Dive into the research topics of 'Surveillance of Low-Grade Appendiceal Mucinous Neoplasms With Peritoneal Metastases After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Are 5 Years Enough? (
  • Conclusions: In the largest series to date, we found temporal bone metastases more frequently than previously reported. (
  • Morton ALButler SAKhan AJohnson AMiddleton P Temporal bone metastases: pathophysiology and imaging. (
  • 1069 Gastric Neuroendocrine Neoplasms and Long-Term Proton Pump Inhibitors: Need for a Revision of Classifications? (
  • Metastases from NMMN are rare and account for less than 1% of all mammary malignant neoplasms in clinical series, and up to 5% of autopsies of patients who die as a result of NMMN ( 1 ). (
  • There have been significant changes in the evaluation and management of lymphatic metastases in the neck during the past several decades, and knowledge of the functional anatomy of the cervical lymphatics is fundamental to the clinical management of metastasis in this region. (
  • The data also suggest that blockade of the ET-1 axis may prevent lung metastasis, a new therapeutic concept that warrants clinical evaluation. (
  • Endobronchial metastases, which are most common with renal cell, melanoma, and lymphomas, are likely to have these same symptoms. (
  • Here, we report a rare case of woman who has severe hepatomegaly due to multiple hepatic metastases of SPN of pancreas. (
  • After 2 years of follow up, multiple small hepatic metastases were presented. (
  • With some malignancies, such as those involving the colon or kidney, the treatment for multiple pulmonary metastases may be resection, but chemotherapy may offer the best option for other malignancies. (
  • The molecular basis of pulmonary metastases is not well understood but is likely to involve the progressive loss of suppressor genes and dominant gain of function mutations in critical pathways along steps of the metastatic cascade ( 3 ). (
  • What Symptoms Are Associated With a Neoplasm? (
  • What Symptoms Occur With Bone Metastasis? (
  • Symptoms of bone metastasis include bone pain, leg weakness, broken bones and high levels of calcium in the blood. (
  • What are the signs and symptoms of bone metastasis? (
  • Receipt of radiopharmaceutical treatment or radiotherapy for treatment of bone metastasis within 30 days of the Baseline Assessment Period. (
  • To date, vitamin D levels have not been previously evaluated in patients with pancreatic neuroendocrine neoplasms (pNENs). (
  • Pathogenesis of bone metastases: role of tumor-related proteins. (
  • In approximately one-third of the cases, the metastasis in the breast is the first presentation of the NMMN. (
  • If hematopoietic and lymphoid neoplasms are excluded, the most common NMMNs that secondarily involve the breast include carcinomas of the lung, ovary, stomach, kidney, and cutaneous melanoma. (
  • Homo sapiens longevity assurance homologue 2 of yeast LAG1 (LASS2), also known as tumor metastasis suppressor gene 1 (TMSG1), is a newly found tumor metastasis suppressor gene in 1999. (
  • Taken together, these experiments show a novel approach of identifying therapeutic targets downstream of metastasis suppressor genes. (
  • Perioperative glucocorticoids have the potential to increase the risk of tumor metastasis. (
  • Preliminary studies showed that it not only suppressed tumor growth but also closely related to tumor metastasis, however, its molecular mechanisms is still unclear. (
  • Solid pseudo-papillary neoplasm (SPN) of pancreas is a rare epithelial neoplasm of pancreas with a low malignant potential, occurs most commonly in young females. (
  • Lesurtel M, Nagorney DM, Mazzaferro V, Jensen RT, Poston GJ (2015) When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? (
  • All three cases showed metachronous multiple liver metastases after 9-13 years of follow-up for EMR, despite achieving complete resection and without muscular invasion. (
  • Calcific deposits are uncommon in metastases from NMMN but may occur in metastatic mullerian (tubal, ovarian, or peritoneal) carcinomas ( 4 , 5 ). (